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Polyglutamine-expanded fragments, derived from the human huntingtin protein, 
are aggregation-prone and toxic in yeast cells, bearing endogenous QN-rich proteins in 
the aggregated (prion) form. Attachment of the proline-rich region targets polyglutamine 
aggregates to the large perinuclear deposit (aggresome). Aggresome targeting ameliorates 
polyglutamine cytotoxicity in the presence of the prion form of Rnq1 protein, however, 
aggresome-forming construct remains toxic in the presence of the prion form of 
translation termination (release) factor Sup35 (eRF3).  
Disomy by chromosome II partly ameliorates polyglutamine toxicity in the strains 
containing Sup35 prion. The chromosome II gene, coding for another release factor, and 
interaction partner of Sup35, named Sup45 (eRF1), is responsible for amelioration of 
toxicity. Plasmid-mediated overproduction of Sup45, or expression of the Sup35 
derivative that lacks the QN-rich domain and is unable to be incorporated into prion 
aggregates, also ameliorate polyglutamine toxicity. Protein analysis indicates that 
polyglutamines alter aggregation patterns of the Sup35 prion and promote aggregation of 
Sup45, while excess Sup45 counteracts these effects.  
In the absence of Sup35 prion, disomy by chromosome II is still able to decrease 
polyglutamine toxicity. However, SUP45 is no longer the gene responsible for such an 
effect. Taken together with the finding that the presence of both the Rnq1 prion and the 
Sup35 prion has an additive effect on polyQ toxicity, one gene or few genes on 
chromosome II are able to ameliorate polyQ toxicity through a SUP45-independent 
pathway. The identification of such a gene is currently ongoing. 
 xvii 
Monosomy by chromosome VIII in diploid heterozygous by AQT (Anti-polyQ 
Toxicity mutants that are disomic by chromosome II) counteracted the effect of AQT. 
Similarly, deletion of the arg4 gene in chromosome VIII in AQT haploid was able to 
eliminate the AQT effect. Moreover, analysis of genes involved in the arginine and 
polyamine synthesis indicated that loss of genes in later stages of arginine biosynthesis 
causes increase of polyglutamine toxicity. Deletion of genes arg1, arg4, arg8 (arginine 
pathway) and spe1 (polyamine pathway) all suppressed the Sup35 prion phenotype 
expression in the nonsense suppression system. Further analysis regarding the 
mechanisms behind those effects is needed. 
Our data uncover the mechanisms by which genetic and epigenetic factors may 
influence polyglutamine toxicity, and demonstrate that one and the same type of 
polyglutamine deposits could be cytoprotective or cytotoxic, depending on the prion 





Huntington Disease is a Polyglutamine Disease 
There are nine human genetic disorders that have been confirmed to be associated 
with expansions of polyglutamine (polyQ) repeats in certain proteins (for a list of these 
diseases, see Table 1.1) (Shao and Diamond 2007; La Spada and Taylor 2010). One well 
known example is Huntington’s disease (HD), which is caused by an expansion of the 
polyQ stretch, located within the N-terminal stretch of the essential protein called 
huntingtin (Htt) (The Huntington's Disease Collaborative Research Group 1993). PolyQ 
expansion promotes formation of aggregates by the proteolytic Htt fragments, containing 
an expanded polyQ stretch (DiFiglia et al. 1997; Lunkes et al. 2002). As polyQ-expanded 
N-terminal region of Htt is shown to aggregate and produce HD-like neurodegeneration 
in the mouse model, it is clear that this region is sufficient for reproducing the 
characteristic features of polyQ aggregation and toxicity (Mangiarini et al. 1996; Stack et 
al. 2005). PolyQ associated pathologies cannot be explained solely by the loss of the 
cellular function of respective protein, e.g. Htt (for review, see Shao and Diamond 2007). 
Sequestration of other essential proteins by polyQ aggregates was proposed as a possible 
mechanism of toxicity (Zoghbi and Orr 1999; Shao and Diamond 2007). However, 
different experimental models suggested different candidates for sequestration (Steffan et 
al. 2000; Hay et al. 2004; Ravikumar et al. 2004; Yamanaka et al. 2010), which decreased 
enthusiasm towards the sequestration model.  
 
Table 1.1 List of polyglutamine diseases 














9-36  38-62  
Huntington disease  HD  autosomal 
dominant  
huntingtin  6-35  36-121  
Dentatorubral-pallidoluys





atrophin-1  6-35  49-88  
Spinocerebellar ataxia 
type 1  
SCA1  autosomal 
dominant  
ataxin-1  6-44  39-82  
Spinocerebellar ataxia 
type 2  
SCA2  autosomal 
dominant  
ataxin-2  15-31  36-63  
Spinocerebellar ataxia 
type 3  
SCA3  autosomal 
dominant  
ataxin-3  12-40  55-84  
Spinocerebellar ataxia 
type 6  
SCA6  autosomal 
dominant  
a1A-voltage-depend
ent calcium channel 
subunit  
4-18  21-33  
Spinocerebellar ataxia 
type 7  
SCA7  autosomal 
dominant  
ataxin-7  4-35  37-306  
Spinocerebellar ataxia 
type 17  




25-42  45-63  
 
To complicate the matters further, polyQ expanded proteins form various types of 
aggregates in mammalian cells (Ross and Poirier 2004; Hands and Wyttenbach 2010). In 
case of Htt, both nuclear and cytoplasmic aggregates were found (Davies et al. 1997; 
DiFiglia et al. 1997; Scherzinger et al. 1997). Their contributions to polyQ 
pathogeneceity remain a topic of intense discussions (Ross et al. 1999; Ross and Tabrizi 
2011). At least, most researchers agree that one type of cytoplasmic aggregated structures, 
so-called aggresome, plays a cytoprotective role via assembling polyQ expanded Htt at 
one site and possibly promoting its autophagy-dependent clearance (Johnston et al. 1998; 
Waelter et al. 2001; Taylor et al. 2003; Olzmann et al. 2008). Aggresome is located 
perinuclearly, associated with the centrosome and assembled with the participation of 
microtubular cytoskeleton. Other misfolded proteins can also be sequestered into an 
aggresome, indicating that this structure serves as a universal quality control deposit of 
aggregating proteins (Johnston et al. 1998; Kopito 2000; Garcia-Mata et al. 2002; 
Olzmann et al. 2007; Chin et al. 2010; Bondzi et al. 2011).  
Yeast Model of Huntington’s Disease and Role of Prions in Polyglutamine Toxicity 
Experimental assays for studying the molecular mechanism of polyQ aggregation 
and toxicity have been developed in yeast Saccharomyces cerevisiae (Krobitsch and 
Lindquist 2000; Muchowski et al. 2000; Meriin et al. 2002; Duennwald et al. 2006). It 
has been shown that cytoplasmic aggregation and toxicity of the chimeric protein, 
generated by a fusion of the expanded polyQ stretch of Htt to the green fluorescent 
protein (GFP), is facilitated by the presence of the endogenous yeast prions, [PIN+] 
and/or [PSI+] (Meriin et al. 2002; Gokhale et al. 2005). In the absence of a prion, 
aggregates of polyglutamine construct were rare and no significant cytotoxicity was 
detected while in the presence of a prion, multiple peripherally located aggregates were 
formed and cytotoxicity was observed (Meriin et al. 2002).   
Prions are self-perpetuating protein isoforms that are able to convert the normal 
soluble protein of the same amino acid sequence into the prion form (Figure 1.1A). 
Prions form fiber like aggregates, called amyloids. Yeast prions [PSI+] and [PIN+] are 
prion isoforms of Sup35 and Rnq1, respectively (for review, see Wickner et al. 2007). 
Sup35 is the yeast translation termination factor (or release factor), eRF3. Molecular 
function of Rnq1 and biological process it’s involved in remain unknown. Both [PSI+] 
and [PIN+] are proteins containing glutamine/asparagine-rich (QN rich) regions within 
the prion domains (PrD) that are responsible for aggregation properties (for review, see 
Tuite and Cox 2003; Inge-Vechtomov et al. 2007) (Figure 1.1B). [PIN+] is required for 
de novo [PSI+] induction by overexpressing Sup35 (Tuite and Cox 2003). Normally, 
yeast cells are still viable when there are prion aggregates inside the cells. However, they 
are disadvantageous to natural populations (Chernoff et al. 2000) and overproduction of 
prion proteins is toxic to the cells (Chernoff et al. 1992). 
Figure 1.1 Yeast prions [PSI+] and [PIN+] are proteins with QN rich regions.
A – Cycle of prion propagation. Prion proteins (square) serve as nuclei, converting 
soluble proteins (eclipse) into prion form. Elongated amyloid fibers generate prion 
“seeds”, which participate in non-prion protein conformational change and 
polymerization.
B – QN rich regions in [PSI+] and [PIN+] prions. [PSI+] is the prion form of translation 
termination factor Sup35, which has a QN-rich stretch in the N-terminal end of the 
prion domain. [PIN+] is the prion form of a protein of unknown function, Rnq1, which 
has multiple QN-rich stretches in the C-terminal prion domain.
A
B






Translation termination factor Sup35 (eRF3)
(prion isoform – [PSI+])
Prion domain
1 153 405 
Protein of unknown function Rnq1  
(prion isoform – [PIN+])
N M C
1 124 254 68541
QN-rich stretch
197 218 262 282 319 338
QN-rich stretches
It is likely that pre-existing prion aggregates nucleate aggregation of polyQ 
expanded huntingtin. In case of Rnq1 prion, it was shown that polyQ aggregates 
sequester some cytoskeletal components and inhibit endocytosis, which apparently 
contributes to cytotoxicity (Meriin et al. 2003). Inhibition of endocytosis was also 
detected in the mammalian cells, expressing polyQ (Meriin et al. 2007). As mammalian 
Htt has been proposed to play a role in vesicle trafficking (Caviston and Holzbaur 2009), 
these results are likely relevant to human HD. 
In the yeast strains containing Rnq1 prion, cytotoxicity was eliminated by using a 
longer Htt fragment, which includes a proline (P)-rich stretch in addition to polyQ (Wang 
et al. 2009). This P-rich stretch was shown to target aggregated polyQ protein into a 
single perinuclear microtubule-dependent deposit, co-localized with the spindle body 
(yeast counterpart of a centrosome) and therefore resembling mammalian aggresome 
(Wang et al. 2009).  Cytoprotective role of aggresome as opposed to cytotoxicity of 
some other types of aggregates recapitulates the situation previously observed in 
mammalian cells (Kopito 2000; Waelter et al. 2001; Taylor et al. 2003). 
Translation Termination Factors in Yeast 
Translation termination is a crucial process in the cells. It ensures the proper 
information transfer from mRNA to proteins, which eventually function in all aspects of 
the life cycle of the cells. In E. coli, RFs are discovered first in the 1960s. RF1 recognizes 
stop codons UAA and UGA, whereas RF2 recognizes UAG stop codon (Scolnick et al. 
1968). A third release factor was discovered to stimulate RF1 and RF2 acitivity. In yeast 
Saccharomyces cerevisiae, two independent genes were identified genetically and 
biochemically as eRF1 and eRF3. Sup45 (eRF1), which is a class I release factor, plays 
the role of recognizing all three stop codons at the ribosomal A site (Figure 1.2A). Sup35 
(eRF2) is a GTPase, which carries out GTP hydrolysis in translation termination. As 
previously introduced, [PSI+] is the prion form of Sup35. The presence of [PSI+] affects 
the translational fidelity, and causes nonsense suppression.  
A nonsense suppression system was developed to monitor [PSI+] phenotypically 
(Inge-Vechtomov et al. 1988) (Figure 1.2B). The ade1-14 allele that has a premature 
UGA stop codon was generated. ADE1 codes for 
N-succinyl-5-aminoimidazole-4-carboxamide ribotide (SAICAR) synthetase, which is 
involved in Adenine biosynthesis. In the presence of [PSI+], full length Ade1 protein is 
synthesized due to the nonsense suppression. Therefore, strains bearing [PSI+] prion are 
able to grow on -Ade medium. On the contrary, [psi-] strains are not able to grow on -Ade 
medium since functional Ade1 protein cannot be produced. Additionally, red 
intermediate compounds of Adenine synthesis accumulate in [psi-] cells, and result in a 
red color on YPD medium. 
Figure 1.2 Translation termination in yeast.
A – Schematic structure of translation termination factor Sup45 (eRF1). N-domain of 
Sup45 is responsible for stop codon recognition; M-domain interacts with peptidyl-
tRNA; C-terminal end is crucial for interaction with another translation termination 
factor Sup35.
B – Nonsense suppression system is used to detect [PSI+]. In the presence of [PSI+], 
most soluble Sup35 is converted to prion form, resulting in nonsense suppression at 
the premature UGA stop codon in ade1-14 allele. Complete Ade1 protein is made, and 
Adenine biosynthesis is able to be accomplished. Cells are able to grow on –Ade 
medium, and exhibit white color on YPD. When there is no [PSI+], sufficient level of 
Sup35 soluble protein ensures the translation fidelity. No complete Ade1 protein is 
synthesized. Therefore, cells are not able to grow on –Ade medium, and the color of 
























Spontaneous Mutants with Decreased Polyglutamine Toxicity was Isolated from 
Strain with Ubc4 Deletion 
To distinguish between the different patterns of polyQ aggregation in yeast, we 
have employed the previously described constructs (Figure 1.3A) that produce the 
N-proximal region of Htt, fused to the FLAG epitope at the N-terminus and the green 
fluorescent protein (GFP) at the C-terminus. The N-terminal Htt region included the 
polyQ stretch, which is either followed (polyQP) or not followed (polyQ) by the P-rich 
region. The polyQ expanded versions (103Q and 103QP) contained a stretch of 103 
glutamine residues, which corresponds to a severe form of Huntington’s Disease, while 
control non-aggregating versions (25Q and 25QP) contained 25 glutamine residues. As 
there was no difference in the effects of 25Q and 25QP, some of the figures show only 
25Q control. As described previously, 103Q construct was toxic to both [PIN+] yeast 
strains (containing Rnq1 protein in a prion form) and [PSI+] yeast strains (containing 
Sup35 protein in a prion form), with a combination of both prions showing an additive 
effect (Figure 1.3B). Also in an agreement with the previous observations, 103QP 
construct was not toxic to the strains containing only [PIN+] prion. Surprisingly, the 
103QP construct was toxic to the strains containing [PSI+] prion, independently of the 
presence and absence of [PIN+] prion (Figure 1.3B). Fluorescence microscopy confirmed 
that 103QP preferentially formed a single perinuclear aggregate deposit (aggresome) in 
the cells containing [PIN+] and/or [PSI+] prions, while 103Q produced multiple 
Figure 1.3 Polyglutamine toxicity and aggregation in the yeast strains with various 
prion compositions.
A – Polyglutamine constructs used in this work. All constructs were under the control 
of the galactose-inducible promoter (PGAL), and contained the FLAG epitope, N-
terminal 17 amino acid residues and poly-Q stretch of human Htt, and were fused to 
the gene coding for green fluorescent protein (GFP) at C-terminus. Numbers indicate 
length of poly-Q stretch.  Poly-QP constructs also contained the proline-rich region of 
Htt (designated as P), immediately following the poly-Q stretch. 
B – Expanded poly-Q without a P-rich region (103Q) is toxic in the presence of either 
[PIN+] or [PSI+] (or both), with two prions showing an additive effect, while expanded 
poly-Q with a P-rich region is toxic only in the presence  of [PIN+] and [PSI+]. The 
25Q construct, not exhibiting toxicity under these conditions, is shown as a control. 
The 25QP construct (not shown) behaved in the same way as 25Q. 
C – 103Q and 103QP form multiple peripheral aggregates and single aggregate 
(aggresome), respectively, in cells containing either or both prions ([PIN+] and/or 
[PSI+]), as visualized by fluorescence microscopy. Perinuclear location of aggresome
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peripheral aggregates (Figure 1.3C). Therefore, ability of polyQP to form an aggresome 
was not affected by the [PSI+] prion. However, the ability of aggresome to ameliorate 
toxicity was impaired.  These data show that the mechanisms of polyglutamine toxicity, 
promoted by the [PSI+] prion, are different from the mechanism of polyglutamine 
toxicity promoted by the [PIN+] prion. 
As ubiquitin-proteasome system (UPS) is known to influence polyQ effects in 
mammalian cells, we have studied polyQ toxicity in the yeast strain with a deletion of the 
UBC4 gene, coding for one of the major yeast ubiquitin-conjugating enzymes (Seufert 
and Jentsch 1990). In both WT and ubc4Δ strains, 103Q and 103QP cause severe toxicity, 
respectively (Figure 1.4A). However, spontaneous papillation occurred frequently to 
ubc4Δ strain instead of WT. Three independent papillae were colony purified and 
confirmed to retain [PSI+] and [PIN+] prions (Figure 1.4B). Each isolate was confirmed 
to stably reproduce the anti-toxic phenotype (Figure 1.4C), and also to ameliorate toxicity 
of 103QP (Figure 1.4D). These derivatives were named AQT for Anti-polyQ Toxicity, 
with respective phenotype designated as Aqt+. The Aqt+ phenotype was dominant in the 
ubc4Δ background (Figure 1.4E), and was partly, although not completely suppressed by 
reintroduction of the wild-type UBC4 gene (Figure 1.4F). In each derivative, the Aqt+ 
trait segregated in a Mendelian fashion in meiosis (Table 1.2).  
 
 
Figure 1.4 Isolation and characterization of Anti-polyQ toxicity (AQT) derivatives.
A – Ubc4Δ has no effect on toxicity of 103Q but slightly ameliorates toxicity of 
103QP in the [PIN+ PSI+] background. 
B – Papillae arise spontaneously in the ubc4Δ [PIN+ PSI+] strain expressing 103Q, and 
are able to stably maintain the anti-polyQ-toxic phenotype after colony purification.
C – Comparison of the growth curves of ubc4Δ [PIN+ PSI+] strains that differ by 
polyglutamine constructs and by the presence or absence of AQT. Growth was 
measured by optical density at 600 nm in the liquid –Ura medium with galactose and 
raffinose instead of glucose. At least 3 independent cultures were characterized per 
each combination. Error bars represent standard deviations.
D – AQT is able to ameliorate 103QP toxicity.
E – AQT is dominant (all strains are [PIN+ PSI+] and ubc4Δ homozygotes.
F – Reintroduction of the UBC4 gene under galactose-inducible promoter on a 
multicopy plasmid partly suppresses but does not completely eliminate anti-toxic 
effect of AQT. Plates were scanned after 10 (B and F) days of incubation.
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Table 1.2 Mendelian inheritance of AQT. 
AQT isolate 
Numbers of tetrads with AQT:WT ratios Total number 
of tetrads 4:0 3:1 2:2 1:3 0:4 
AQT2 0 0 5 0 2 7 
AQT7 0 0 10 0 3 13 
AQT9 0 0 8 0 0 8 
 
Each AQT strain was mated to the isogenic wild type (WT) ubc4Δ strain of the 
opposite mating type. 
 
All pairwise genetic crosses between three independent AQT derivatives produced 
4 AQT: 0 wild-type pattern of segregation in the vast majority of tetrads (Table 1.3), 
indicating that all AQT derivatives are formally confined to a single genetic locus. 
 
Table 1.3 Recombination test for allelism of AQT derivatives. 
Crosses AQT: WT ratios* 
Total number of tetrads 
analyzed 
AQT2 X AQT7 4:0 (6)** 7 
AQT2 X AQT9 4:0 (8) 8 
AQT7 X AQT9 4:0 (9) 9 
 
All crosses were performed in the ubc4Δ [PIN+ PSI+] background. 
* In parentheses, number of tetrads showing a respective ratio. 
** One exceptional tetrad with 3:1 ratio was recovered. 
 
Characterization of AQT Mutants 
Despite their anti-toxic effect, AQT derivatives retained the typical mode of 
cytologically detectable aggregation for both 103Q (multiple peripheral aggregates, 
Figure 1.5A) and 103QP (single perinuclear aggregate, Figure 1.5B), indicating that 
amelioration of toxicity is not due to lack of aggregation.  
Overproduction of Sup35 protein or its prion domain, Sup35N, is known to inhibit 
growth of the [PSI+] strains. This effect was ameliorated in AQT derivatives (Figure 
1.5C). Interestingly, ubc4Δ increased temperature sensitivity of our strains to 
near-permissive conditions, and this phenotype was also ameliorated in AQT derivatives 
(Figure 1.5D). 
Objectives 
The main goal of this study is to identify genetic factors that are able to modulate 
polyglutamine toxicity in the yeast model, and to understand the mechanism by 
characterizing the interaction among those factor, yeast prions, and ubiquitin-proteasome 
system. Utilizing the well established yeast model of Huntington Disease, we hope our 
findings would shed some light on pathology of polyglutamine diseases in humans and 
treatment strategies. 
Figure 1.5 Phenotypes associated with AQT.
A and B – Typical aggregation patterns of 103Q (multiple dots, A) and 103QP (single 
clump, B) are not affected by AQT, as confirmed by fluorescence microscopy.
C – AQT mutant ameliorates toxicity of excess Sup35 or Sup35N in the [PSI+] strain. 
Sup35 and sup35N proteins were expressed from centromeric plasmid under control 
of the galactose-inducible promoter. Cultures were grown in the -Ura glucose medium 
selective for the plasmid for 1 day. Serial decimal dilutions were plated onto -Ura
glucose/raffinose medium.
D – AQT ameliorates temperature sensitivity of the ubc4Δ strain. Growth of ubc4Δ at 
39oC is completely inhibited, while isogenic WT strain and AQT ubc4Δ strain are 
slightly growing. Deletion of ubc4 causes temperature sensitivity at 39°C. AQT 
mutant compensates for the effect of ubc4Δ and display temperature resistance at 
39°C. Cultures were grown in the YPD liquid medium for 1 day and serial decimal 
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All yeast strains used in this study are listed in APPENDIX A Table A.1. Detailed 
description and additional information are stated in the corresponding chapters. Strains 
used in this study are [PSI+][PIN+], [psi-][PIN+], [psi-][pin-], and [PSI+][pin-] derivatives 
of strain GT81-1C(Chernoff et al. 1999; Chernoff et al. 2000). GT81-1C is considered the 
wild type strain in this study, and GT349 is the isogenic strain of GT81-1C with deletion 
of gene ubc4. GT573, GT574 and GT575 are the spontaneous mutants obtained from 
polyglutamine cytotoxicity plate assay. Among the three mutants, GT574, which is the 
No. 7 AQT mutant, is most commonly used throughout this study.  
Plasmids  
Plasmids used in this study are listed in APPENDIX B Table B.1, in which the 
yeast selection markers and plasmid types are included. PolyQ/QP producing constructs 
were described previously (Meriin et al. 2002; Wang et al. 2009). Centromeric plasmids 
bearing wild type or mutant (sup45-103) alleles of SUP45 gene under its endogenous 
promoter (Le Goff et al. 2002; Moskalenko et al. 2004) were a gift of G. Zhouravleva (St. 
Petersburg State University). Plasmid CEN-SUP45ΔC19, bearing the deletion of 19 
C-terminal codons in SUP45, that impairs protein function and its interaction with Sup35 
(Kallmeyer et al. 2006), was a gift of D. Bedwell (University of Alabama at Birmingham). 
Centromeric plasmid bearing the SUP45ΔC5 allele that lacks 5 C-terminal codons and 
causes only slight impairment of Sup45 function, was constructed inserting the 5.1kb 
BamHI-HindIII fragment, containing SUP45 gene, from plasmid Yep13-SUP1 (Chernoff 
et al. 1992), into the BamHI-HindIII digested vector pRS315 (Sikorski and Hieter 1989). 
The galactose-inducible SUP45 plasmid, containing the SUP45 cDNA under the control 
of GAL1 promoter, was previously isolated in Chernoff laboratory in a library screen 
aimed at amelioration of excess Sup35 toxicity. The CEN-SUP35C plasmid was 
constructed by inserting the PstI-XbaI fragment, bearing the SUP35C region under the 
endogenous SUP35 promoter, from plasmid pEMBL-yex-SUP35 del3ATG 
(Ter-Avanesyan et al. 1993), into pRS315. The EcoRI-SacII fragment containing copper 
promoter and NM domains of Sup35 from plasmid pmCUPNMsGFP (Serio et al. 1999) 
was inserted into the corresponding sites in vector pRS315, and DsRed2 from 
pDsRed2-N1 (Clontech) was fused in frame with the Sup35NM to yield the plasmid 
pCUP-Sup35NM-DsRed. The plasmid overexpressing UBC4 was constructed by 
subcloning the UBC4 ORF between the GAL1 promoter and CYC1 terminator in pTRP 
(Laney and Hochstrasser 2003). Plasmids carrying the promoter and N-terminal domains 
of the yeast PGK gene, fused to the bacterial β-galactosidase (lacZ) gene either in frame 
or via a UGA stop codon (Firoozan et al. 1991) were a gift of M. Tuite (University of 
Kent). 
Primers  
Primers used in this study were synthesized DNA oligonucleotides without 
modifications from Invitrogen and IDT. Refer to Appendix C for a full list of primers. 
Antibodies  
Rabbit polyclonal antibodies to Sup35C and Sup45 were generous gifts from Dr. 
D. Bedwell. Anti-GFP, N-terminal antibody produced in rabbit was purchased from 
Sigma-Aldrich. Purified Ade2p, kindly provided by Dr. V. Alenin, was used to raise 
rabbit polyclonal antibody to Ade2 by Cocalico, Inc. 
Secondary antibody, Anti-Rabbit HRP, for regular Western Blot experiments was 
purchased from Sigma-Aldrich. DyLight 549 Goat Anti-Rabbit secondary antibody, from 
Jackson ImmunoResearch Laboratories, Inc., was used for immunofluorescence 
microscopy. 
Methods 
Standard Yeast Media and Growth Conditions 
Standard yeast media, procedures (including transformation, phenotype scoring, 
velveteen replica plating, mating and sporulations) were used (Sherman 2002).  
Synthetic complete media lacking adenine, leucine, uracil, tryptophan, and 
histidine were designated as -Ade, -Leu, -Ura, -Trp and -His, respectively. Induction 
media for GAL-inducible plasmid constructs contained 2% galactose instead of dextrose 
for plate assays and additional 2% raffinose was added for the induction in liquid cultures. 
200 μM CuSO4 was used to induce genes under the CUP promoter. Yeast cultures were 
grown at 30°C except for the temperature-sensitivity assays (employing 39°C). Liquid 
cultures took up at least 1/5 volumeric ratio of liquid/flask and grew in the 30°C shaking 
incubator at the speed of 200-250 rpm. 
To prepare diploid cell for tetrad dissection experiments, cells were patched onto 
presporulation medium (0.8% yeast extract; 0.3% peptone; 10% dextrose; 1.5% agar and 
10X adenine) overnight prior to being patched onto sporulation medium (10 mM 
CH3COOK; 0.05% dextrose; 0.1% yeast extract; 1.5% agar; amino acids of 
corresponding auxotrophic markers). 
E. coli Transformation 
Competent E. coli Dh5α cells were thawed on ice. Aliquot 50 μl cell 
suspensions for each transformation reaction. Add 1 μl plasmid and mix well with 
competent cells. Let tube stand on ice for 30min before a heatshock at 42°C for 30 sec. 
Insert tube into ice immediately after heatshock to cool for 1-2 min. Add prewarmed 
SOC 500 μl and incubate with rotation at 37°C for 1 hour. Collect cells at 6000 rpm for 2 
min. Discard the supernatant and plate all cells onto LB agar medium with proper 
selectable antibiotic marker carried by the plasmid. 
Yeast Transformation 
Yeast transformation was done according to the standard protocol using the 
lithium treatment approach with minor modifications. Tranformation mixture was 
heatshocked at 42°C for 5-7 min, and plated onto synthetic dropout media selecting the 
appropriate auxotrophic markers beared by the plasmids or plated onto YPD for 1 day 
before being replica plated onto antibiotic containing YPD if the selectable marker is an 
antibiotic resistant gene. 
Micromanipulation 
Cells were incubated on sporulation medium for 3-5 days. Sporulation was 
confirmed first by resuspending a small aliquot of sporulating culture into 5 μl water and 
checking under the microscopy. Resuspend sporulating culture in 40 μl ddH2O with 2 μl 
of 4 mg/ml lyticase. Incubate at 37°C for 10 min. Spin cells down at 3000 rpm for 1min. 
Discard the supernatant and gently resuspend cell pellet in 300 μl ddH2O. Transfer 10-20 
μl the lyticase treated diploid cells onto the dissecting plate and let it dry. Tetrad 
dissection was performed by using MSM System 300 micromanipulator from Singer 
Instrument Co. Ltd. 
Thermotolerance Assay 
Thermotolerance assay was used to test the thermoresistance of AQT strain and its 
derivatives on the growth at 39°C. Cultures were grown in liquid media for 1 day and 
counted using the hemocytometer. Adjust the cell concentrations of each culture 
according to the cell counts, and make serial dilution spotting onto appropriate media. 
Pictures were scanned after 2 days of incubation in 30°C (control) and 39°C. 
Plate Assay for Polyglutamine Cytotoxicity 
Polyglutamine cytotoxicity was detected as growth inhibition on the synthetic 
dropout medium with galactose instead of glucose where polyglutamine constructs were 
selectively maintained and induced. Unless specified otherwise, velveteening plates were 
scanned after 5-6 days of incubation after a second passage from galactose medium, and 
spotting plates were scanned after 3-5 days of incubation. 
Bacterial Plasmid DNA Isolation 
Alkaline lysis method(Sambrook and Russell 2001) with modifications is used for 
both mini-prep and maxi-prep of plasmid DNA from E. coli. A single colony is 
inoculated into LB liquid medium (10g/L tryptone, 5g/L yeast extract, 10g/L NaCl, pH 
7.0) with proper antibiotic (ie, 50 μg/ml Ampicilin) to grow overnight. Cells are pelleted 
at 10,000 rpm for 10min and resuspended with 1X TE buffer (100mM Tris-HCl, 10mM 
EDTA, pH 8.0). Solution II (0.2M NaOH, 1% SDS) is added to the cell suspension. Mix 
by inverting tubes for 5 times, then add solution III (3M KAc, pH 5.0). Invert tubes for 5 
times and place on ice for 5min. Volumes of solution I, II and III added should follow the 
ratio 1:2:1.5. Spin lysed cell suspension at 10,000 rpm for 20min to pellet cell debris. 
Transfer the supernatant into a new tube, mix with 0.6 volume of isopropanol, and 
incubate on ice for 15min. Centrifuge at 10,000 rpm for 10min. Add 0.5ml of ddH2O to 
resolve the pellet and transfer to an eppendorf tube. Add 0.3ml 9M (NH4)Ac, incubate at 
-20°C for 20min, then spin at 13,000 rpm for 5 min. Transfer the supernatant into a new 
tube and mix well with 0.6 volume of isopropanol, then incubate on ice for 15min. Pellet 
DNA by spinning at 13,000 rpm for 5min. Wash the pellet with 1ml 70% ethanol, 
centrifuge again, and discard the supernatant as much as possible. Briefly dry the pellet, 
then dissolve it in ddH2O with 0.1mg/ml RNase. 
Yeast Plasmid DNA Isolation 
Grow yeast in 50ml of selective medium to OD ~ 1.5 at 600nm. Collect cells, 
resuspend the cells in 0.5ml of (1M Sorbitol, 0.1M EDTA, pH 8.0). Add 20μl of 4mg/ml 
Lyticase solution and incubate at 37°C for 2 hours. Centrifuge at 3000 rpm for 1min, and 
remove the supernatant as much as possible, then resuspend the cells in 200μl of TE by 
pipetting gently. Mix with 400μl of (0.2M NaOH, 1% SDS) by inverting the tube several 
times. Incubate at room temperature for 30min. Add 300μl of 5M KAc, pH 4.8. Place on 
ice for at least 30min. Centrifuge for 10min at 4°C. Transfer the supernatant to a new 
tube and add 600μl of isopropanol. Mix by inversion. Incubate for 20min at room 
temperature, then centrifuge for 5min at 13,000 rpmn. Wash with 70% ethanol. Spin at 
13,000 rpm for 5min, then dry the pellet briefly. Resuspend the pellet in 50μl of ddH2O. 
Take 10-15μl to transform a 50μl culture of E. coli competent cells.  
Yeast Genomic DNA Isolation 
Yeast DNA mini-prep procedure from Methods in Yeast Genetics: A Laboratory 
Course Manual (Sherman et al. 1987) with modifications is used to isolate yeast genomic 
DNA.  
Grow cells overnight to reach stationary phase in YPD liquid medium at 30°C. 
Pellet cells at 3000 rpm for 5min, and then discard the supernatant. Resuspend the cells in 
0.5ml of (1M Sorbitol, 0.1M EDTA, pH 7.5); transfer to an eppendorf tube. Add 20μl of 
4mg/ml lyticase solution and incubate at 37°C for 60-90min. Centrifuge at 4000 rpm for 
1min. Discard the supernatant and resuspend the cells in 0.5ml of (50mM Tris-HCl, 
20mM EDTA, pH 7.4) by pipetting. Add 55μl of 10% SDS, and mix well by inversion. 
Incubate at 65°C for 30min, then add 0.2ml of 5M KAc and incubate on ice for 60min. 
Centrifuge at 13,000 rpm for 5min. Transfer the supernatant to a new eppendorf tube and 
add 0.75ml of isopropanol. Mix by inversion and centrifuge at 13,000 rpm for 5min. 
Wash the pellet with 70% ethanol, spin for 3 min at 13,000 rpm, and briefly dry the pellet. 
Resuspend the pellet in 50-100μl ddH2O with 100μg/ml RNase. Warm pellet to 55°C to 
help dissolve if needed.  
Yeast genomic DNA prepared this way is good for regular PCR reactions. If used 
for sequencing, additional purification steps are required. 
DNA Electrophoresis 
1% argarose in 1X TAE buffer is used to make the DNA electrophoresis gel. 
DNA electrophoresis is run under a constant voltage no more than 10V/cm of the gel. 
DNA bands were visualized  
Restriction Digestion and Ligation 
Digestion and ligation procedures follow the standard protocols(Sambrook and 
Russell 2001). Restriction enzymes are purchased from New England BioLabs, Inc. 
PCR 
PCR reactions were performed according to the standard protocol. Taq DNA 
polymerase with ThermoPol buffer was purchased from New England BioLabs, Inc. 
Phusion High Fidelity PCR Master Mix (manufactured by New England BioLabs) was 
used to amplify DNA fragments longer than 5kb. 
PCR-Based Gene Deletion 
The individual gene deletions were made by using PCR-mediated transplacement 
with the cassette bearing either Schizosaccharomyces pombe HIS5 gene, an ortholog of S. 
cerevisiae HIS3 gene (thus designated in this work as HIS3), or bacterial kanr gene, 
which is resistant to G418 (Longtine et al. 1998). PCR was performed using primers 
containing 40-50 bp homologous sequences flanking the region to be deleted and 20 bp 
complimentary to the plasmid vector bearing the selectable marker. PCR amplified DNA 
fragment was used to transform yeast cells. Transformants were selected either on the 
synthetic dropout medium (auxotrophic gene marker) or plated on YPD for one day 
before being replica plated onto antibiotic containing YPD (antibiotic resistant gene 
marker). Resulting transformants were subject to be confirmed by PCR and sequencing 
analysis. 
Constructions of Chromosomal Deletions 
Chromosomal deletions in the extra copy of chromosome II were made in two 
consecutive steps of PCR-mediated genome alteration. The first step involved the 
insertion of a cassette containing KlURA3 and hyg genes into the targeted regions as 
counterselectable markers (Storici and Resnick 2006); the second step employed the 
replacement of targeted regions with LEU2 gene amplified from vector pRS315 (Sikorski 
and Hieter 1989). Resulting Ura-Leu+ hygromycin sensitive transformants were subject to 
PCR and sequencing analysis to verify the deletions. 
Transposon Mutagenesis and Identification of Insertion Locations 
A transposon insertion library was used in the initial screening of AQT 
gene(Kumar and Snyder 2001). Each plasmid from the insertion library carries a picec of 
yeast genomic DNA with a single random insertion of a bacterial transposon and a 
selectable marker LEU2. The transposon mutagenized library was introduced into yeast 
by regular transformation of the plasmid DNA from each pool (total 15 pools) of the 
library. Library DNA was transformed into E. coli ensuring approximately 100,000 
transformants per pool. Transformants were collected by adding 6 ml of LB medium onto 
the plate and scrape cells off to an eppendorf tube. Resuspended E. coli transformants 
into LB with 3 μg/ml tetracycline and 40 μg/ml kanamycin and grew at 37°C. Saturated 
cell culture was subject to standard plasmid DNA isolation. 
NotI digested insertion library DNA of 2.1 kb length was used to transform yeast 
cells. Total 30,000-50,000 colonies were screened to ensure 95% coverage of the genome. 
Vectorette PCR was used to identify the insertion sites as follows. Yeast genomic DNA 
was digested with AluI, which was intactivated by heating 20 min at 65°C after a 




TC) in 200 μl of annealing buffer (10 mM Tris, 10 mM MgCl2, 50 mM NaCl) at 70°C for 
5 min then slowly cooled to room temperature. The adaptors were ligated with the 
digested genomic DNA fragments. Standard PCR using primers UV and M13-47 (UV: 
CGAATCGTAACCGTTCGTACGAGAATCGCT; M13-47: 
CGCCAGGGTTTTCCCAGTCACGAC) was performed and purified PCR product 
containing piece of yeast genomic DNA that was adjacent to the insertion was sequenced 
with primer PRSQZ (CGACGGGATCCCCCTTAACG). 
Pulse Field Gel Electrophoresis 
Yeast cells were cultured in YPD for 1 day and 2 x108 cells were collected from 
each sample. Treat cells in buffer of (270μl 0.5M EDTA pH 7.5, 3μl 1M Tris, and 30 μl 
5mg/ml lyticase). Add 210 μl 2% low melting temperature agarose (IBI Scientific) gel in 
0.1 EDTA at 42°C. Load agarose cell suspension into the plug mold (Bio-Rad). Plugs 
were incubated in 800μl 0.5M EDTA, 8μl 1M Tris at 37°C for 2-4 hours, then incubated 
at 30°C overnight with addition of 200μl proteinase K (5% sarcosyl, 5mg/ml proteinase 
K in 0.5M EDTA, pH 7.5). Plugs were sliced and equilibrated for 30min in 4 ml of 0.5 X 
TBE prior to loading onto the gel, and then covered with 0.5% agarose gel to 
immobilized the plugs in the gel well. 1.5% agarose gel was used and run in 0.5X TBE 
for 40 hours in Bio-Rad CHEF (Contour-clamped Homogeneous Electric Field) Mapper 
XA following the protocol described previously (Narayanan et al. 2006).  
Southern Blot 
Soak the DNA agarose gel in depurination solution (0.25M HCl) for 10 min, then 
rinse once by dH2O. Denature the DNA for 25min in denaturation solution (1.5M NaCl, 
0.5M NaOH), then rinse once by dH2O. Neutralize for 30 min in neutralization solution 
(1.5M NaCl, 0.5M Tris, 1mM EDTA, pH 7.2), then rinse once by dH2O. DNA was 
transferred to Hybond-N+ membrane (GE Healthcare) by capillary blotting. Specific 
chromosomes were identified by either using Random-Prime kit (GE Healthcare) or P32 
labeled probes. 
Protein Isolation and Differential Centrifugation Assay 
For protein isolation, cells were destroyed by vortexing with glass beads in the 
lysis buffer (25 mM Tris-HCl, pH 7.5; 0.1 M NaCl; 10 mM EDTA; 4 mM PMSF; 200 
μg/ml Cycloheximide; 2 mM Benzamidine; 20 μg/ml Leupeptin; 4 μg/ml Pepstatin A; 1 
mM NEM; Roche cOmplete protein inhibitor cocktails of suggested dose), and cleared of 
cell debris at 735 g. Protein concentrations were measured by Bradford reagent (BioRad) 
and if necessary, verified by coomassie staining of the SDS-PAGE gels. Differential 
centrifugation experiments employed 8,000 g for 10 min at 4°C unless specified 
otherwise. Pellets were resuspended in the volume of lysis buffer that was equivalent to 
the volume of supernatant. Protein samples were always boiled prior to loading onto 
SDS-PAGE.  
SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
Prepare the SDS-polyacrylamide gel as follows: 10% separating gel for two (H2O 
2.64 ml; 30% acrylamide 3.33ml; 2% bis-acrylamide 1.33ml; 1.5M Tris pH 8.8 2.5ml; 10% 
SDS 100 μl; 10% APS 100 μl; TEMED 4μl), and 4% stacking gel for two (H2O 3.1ml; 30% 
acrylamide 0.833ml; 2% bis-acrylamide 0.332 ml; 1M Tris pH 6.8 0.63ml; 10% SDS 
50μl; 10% APS 50μl; TEMED 7μl) 
Electrophoresis was run with electrode buffer (25mM Tris, 192 mM glycine, 0.1% 
SDS, pH 8.3) under 100V for 2-3 hours. 
Semi-Denaturing Detergent – Agarose Gel Electrophoresis 
Semi-Denaturing Detergent-Agarose Gel Electrophoresis (SDD-AGE), used to 
fractionate the SDS-resistant protein polymers according to their sizes, was performed 
according to the standard protocol (Halfmann and Lindquist 2008). Proteins were isolated 
in the same lysis buffer described previously with the exception that the dose of Roch 
cOmplete protein inhibitor cocktails was doubled. Cell debris was cleared by centrifuging 
the lysate at 7000 rpm (4000g) for 2 min. Proteins were diluted in 2% SDS sample buffer, 
incubated for 5 min at room temperature before loading, and run in the 1.5 % agarose gel 
with 0.1% SDS in 1X TAE buffer containing 0.1% SDS at 4°C at 86V for 45 min and 
then 36Vuntil the dye reached 1cm from the end of the gel. 
Western Blotting and Immunodetection 
After SDS-PAGE, proteins were transferred onto Hybond ECL nitrocellulose 
membrane (GE Healthcare) in Wet Blotting System from Bio-Rad at 285 mA for 45 min. 
After SDD-AGE, protein was transferred from agarose gel to nitrocellulose membrane 
(Whatman) by capillary blotting overnight in 1X PBS buffer containing 0.1% SDS. 
Membranes were blocked in 5% non-fat milk for at least 1 hour before reacted to 
proper primary antibodies, and secondary antibodies. Reaction was detected by using the 
chemiluminescent detection reagents as described in the GE Healthcare protocols. 
Densitometry was performed to determine relative protein levels using the VisionWorks 
LS program from UVP (UVP, LLC, Upland, CA). 
Fluorescence Microscopy 
GFP and/or DsRed visualization in live cells was typically performed after 6 
hours of induction in liquid media containing 2% galactose and 2% raffinose, and/or 200 
μM CuSO4, depending on the promoter(s) used. A 5 μl aliquot of culture was place on the 
center of a glass slide and covered with a cover slip. The cover slip was then sealed with 
clear nail polish. Fluorescnece was detected under a BX41 microscope (Olympus) with 
the endow GFP bandpass emission (green) or tetramethyl rhodamine isocyanate 
(rhodamine/Dil; red) filters. 
Immunofluorescence Microscopy 
Immunofluorescence experiments was done following the protocol described 
previously (Wegrzyn et al. 2001). Cultures were in -Ura gal/raf medium for 12 hours 
induction before a final concentration of 4% formaldehyde was added to fix the cells for 
30 min shaking at 25°C. Cells were then spun down at 3000 rpm for 5 min, washed twice 
in solution B (100 mM potassium phosphate buffer pH 7.5, 1.2M sorbitol). Cell pellets 
were resuspended in 0.5 ml solution B with 1 μl of β-mercaptoethanol and 5 μl of 4 
mg/ml lyticase and incubated at 37°C for 30 min. Cells were precipitated again and 
washed twice with solution B. Fixed cells with destroyed cell walls were then 
resuspended in 100 μl of solution F (100 mM potassium phosphate buffer pH 7.4, 
1mg/ml BSA, 15 mM NaN3, 15 mM NaCl) with a 1:500 dilution of appropriate primary 
antibody, incubated for 1 hour, washed 10 times with solution F, and resuspended in 
solution F containing the secondary antibody (see Antibodies), incubated in the dark for 
1 hour, washed 10 time with solution F and resuspended in antibleaching mounting 
solution (1 mg/ml p-phenylenediamine in 1X PBS and 90% glycerol). A 5 μl aliquot was 
place on a glass slide, covered by a cover slip, and sealed in clear nail polish. The slides 
can be stored in the dark at 4°C for a week. 
Confocal Microscopy 
The colocalization experiments were performed by using LSM510 Laser 
Scanning Microscope (Karl Zeiss MicroImaging GmbH, Germany), with argon laser Ex 
488-543 (FITC/CY3), 488 nm for GFP detection, and helium-neon laser Ex 488-543 
(FITC/CY3), 543 nm for red fluorescence detection. The pinhole size was 106 μm. 
Software packages ZEN 2009 and ZEN 2009 Light Edition were used for picture taking 
and analysis. 
Microarray Analysis 
Genomic DNA of AQT derivatives as well as controls was hybridized to the 
complete DNA microarray of the Saccharomyces cerevisiae genome, as described 
previously (Lemoine et al. 2005). Comparative Genomic Hybridization (CGH) analysis 
was performed to determine the copy number of genes in AQT derivatives. The Cluster 
Along Chromosome (CLAC) consensus plot was generated using CGH-Miner (Wang et 
al. 2005). 
Assay for Beta-Galactosidase Activity 
Assay for β-galactosidase activity was performed according to standard protocol 
(Russell et al. 1986). Cultures were first inoculated in -Ura -Trp glucose medium to select 
for both lacZ and polyglutamine plasmids. Cells were collected and washed in ddH2O for 
3 times before introduced into -Ura -Trp galactose/raffinose medium for 24 hours 
induction of overexpression of polyglutamine. Cultures were grown to reach OD600 less 
than 1.0. The OD at 600 nm was measured three times for each sample.Place 1 ml of 
culture into an eppendorf tube (each sample was tested in triplicates), and spun at 
maximal speed for 2 min. Pellet was washed by Z buffer once, and spun at maximal 
speed for 5min. Cell pellet was resuspended in 150 μl of Z buffer with β-mercaptoethanol. 
50 μl of chloroform and 20 μl of 0.1% SDS were added to each tube. Mix by vortexing at 
high speed for 15 sec. 700 μl of pre-warmed (30°C) 1 mg/ml ONPG solution in Z buffer 
with β- mercaptoethanol was added, and time was recorded at this point. Reaction was 
carried out in a 30°C waterbath till a pale yellow color was observed. Reactions were 
stopped by adding 500 μl of 1M Na2CO3 and vortexing for 10 sec. Cell debris was 
pelleted at maximal speed for 2 min. Supernatant was taken for OD measurement at 420 
nm.  
Miller Units was calculated using the following formula (OD420 was the 
absorbance reading at 420 nm, OD600 was the absorbance reading at 600nm, min was the 
reaction time in minutes, ml was the reaction volume in ml): 
Miller Units = (OD420*1000)/(OD600*min*ml) 
CHAPTER 3 
GENETIC BASIS OF AQT 
 
Materials and Methods 
Strains and Plasmids 
Yeast strains GT532-9A and GT532-9C are Aqt- segregants of GT532, which is 
the diploid homozygous by ubc4Δ and heterozygous by AQT, made by crossing AQT 
derivative No. 2 with [pin- psi-] ubc4Δ strain. The resulting diploid served as non-AQT 
control strains in plate toxicity assay for attempt of identification of AQT using 
transposon mutagenesis library. GT532 was used to screen library pools #22, #24, #28, 
#36, and #37. And GT534, made by crossing AQT derivative No. 7 with [pin- psi-] ubc4Δ 
strain was used to screen library pools #21, #23, #25, #26, #27, #29, #31, #34, #35, and 
#38. The strain used for centromere-linked gene deletion was GT532-9A. 
Plasmids bearing 103Q and 25Q with URA3 marker were used in polyglutamine 
toxicity assay on -Ura/Gal medium. Plasmid construct used for centromere-linked gene 
disruption contained Kanrgene, which conferred the resistance to G418, and was 
described in (Longtine et al. 1998) previously. YPD agar plates containing 0.3% G418 
were used to select deletion potentials after yeast plasmid transformation and 1 day 
growth on plain YPD agar plates.  
Methods 
See Chapter 2 Methods for detailed description of pulse field gel electrophoresis, 
and microarray analysis. 
In tetrad analysis, for each experiment at least 20 full tetrads containing 103Q 
plasmid were tested through plate toxicity assay on -Ura/Gal. Genetic locus information 
and gene sequences were obtained from Saccharomyces Genome Database 
(http://www.yeastgenome.org/). 
Results 
Attempt of Identification of AQT gene by Transposon-Mutagenesis 
As previously characterized (see description of characteristics of AQT mutants in 
Chapter 1), AQT was determined to be in a single and the same genetic locus for all three 
isolates and exhibit dominance according to classic tetrad analysis, in which different 
isolates were mated to each other or isogenic WT strain of the opposite mating type. 
In order to identify the gene altered by the AQT mutation, we have attempted the 
transposon mutagenesis approach, aimed at inactivation of the dominant AQT allele in the 
[PSI+] diploid, homozygous by ubc4Δ and heterozygous by AQT. A yeast genomic 
library with transposon insertions was employed (Kumar and Snyder 2001). Each 
plasmid from the transposon mutagenesis library carry a piece of yeast genomic DNA 
flanked by NotI restriction sites (Figure 3.1A), in which a DNA cassette containing 
Figure 3.1 Experimental design of the transposon insertion library screening.
A – Transposon mutagenesis  library. The transposon cassette contains lacZ, LEU2, 
and Amp genes, flanked by Tn3 terminal inverted repeats (TR). The insertion cassette 
was inserted into yeast genome. Each plasmid of the library bears a piece of 
transposon cassette containing yeast DNA with NotI restriction enzyme on the ends. 
The NotI-NotI fragment is used to transform yeast cells, resulting in transformants
with transposon cassette intergrated into the genome.
B –Plate toxicity assay was performed to identify the preliminary potentials for 
additional confirmation. A positive potential out of three potentials shown is indicated 
by the arrow. 
C – Identification of the insertion location using vectorette PCR. AluI digested yeast 
genomic DNA was ligated with adaptors. Primers from inside the bubble of the 
adaptor and gene in the insertion cassette are used to amplify a fragment containing 
the respective pieces of genomic DNA where the insertion happen. Subsequent 
sequencing analysis gives the insertion location information.
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flanking Tn3 terminal inverted repeat, a 5’ truncated lacZ gene for β-glactosidase 
activity assay, a LEU2 gene for plasmid selection in yeast, and an ampr gene for plasmid 
selection in bacteria. 
The NotI digested fragment from each library pool was used to transform the 
[PSI+] diploid, homozygous by ubc4Δ and heterozygous by AQT. The 
transposon-containing cassettes were integrated into the genome via homologous 
recombination. As previously demonstrated, diploid heterozygous by AQT exhibited AQT 
effect in the presence of 103Q due to the dominance of AQT allele, whereas WT 
homozygous by aqt-wt suffered polyglutamine toxicity as shown in Figure 3.1B. 
Transformants were selected on -Ura -Leu medium after transformation to ensure both 
successful insertion of transposon cassettes and the presence of 103Q plasmid. Ura+  
Leu+ transformants were patched as deletion potentials together with proper controls to be 
checked on -Ura -Leu/ Gal medium for polyglutamine toxicity assay. Potentials which 
became Aqt- (pointed by an arrow in Figure 3.1B) were collected for further 
identification. 
To obtain at least 30,000 transformants in total from all 15 pools of library 
plasmids, which ensures the 95% coverage of the yeast genome, no fewer than 50 master 
plates with 55 potentials on each plate were screened for each library pool. 15 potentials 
that have lost Aqt+ were performed the vectorette PCR (Figure 3.1C). Genomic DNA of 
potentials was isolated and digested with AluI restriction enzyme. Adaptors made by 
annealing primers ABP1 and ABP2 at 70°C for 5 min then slowly cooling to room 
temperature in 2 hours. AluI digested genomic fragments were ligated with adaptors. 
Then PCR with primers UV and M13-47 was conducted using the ligation mixture as the 
template. Purified PCR products of 7 out of the 15 potentials were sent out for 
sequencing. Four potentials were identified to have the insertion within an ORF. These 
ORFs are GRS2, MGE1, TID3, and MSS1. However, none of these insertions was linked 
to AQT as demonstrated by sporulation and tetrad analysis (data obtained by Nina 
Romanova), suggesting that in each case, loss of Aqt+ phenotype occurred by a 
mechanism distinct from alteration of the mutant AQT allele.  
Out of 14,000 transformants obtained from 7 pools in screening, 88 potentials 
were isolated. Based on the high possibility that majority of the potentials were false 
positive potentials, an experimental strategy involving extensive genetic crossing, 
sporulation and tetrad dissection were utilized. Potentials were first placed on sporulation 
medium to reach a sporulation rate of at least 10-20%, which was determined by counting 
the tetrads under a microscope. Haploid AQT strain previously transformed with a 
plasmid vector carrying TRP1 gene was plated on YPD to grow to a cell lawn. Potentials 
with sufficient sporulation rate were then velveteened onto the AQT cell lawn on YPD 
and incubated for 1 day. The YPD plate was then velveteened onto -Ura -Leu -Trp 
medium to select diploids that resulted from the crossing of AQT haploid (Trp+) and the 
Aqt- Leu+ (Ura+  Leu+) spore from the Aqt- potential. Each resulting diploid was 
numbered after the same number of the original potential, and colony-purified on -Ura 
-Leu -Trp medium. After such preparation, the potentials were patched on masterplates 
and velveteened onto sporulation medium. After 4-7 days, tetrads were dissected on YPD 
plates and tetrad analysis was conducted. By doing this, we expected the tetrad analysis 
data to fall into 3 categories explained in Figure 3.2. When insertion cassette restored the 
WT aqt by the recombination with flanking homologous sequences, the first sporulation 
would yield all 4 Aqt- spores with a 2:2 ratio of Leu+ : Leu-. By mating the sporulated 
culture with AQT haploid and selecting for the diploids containing both insertion cassette 
and AQT, the second sporulation was expected to yield tetrads of 2 Aqt+  Leu- and 2 Aqt- 
Leu+ spores only (Figure 3.2A). Potential artifacts that were resulted from loss of AQT by 
spontaneous crossingovers and unrelated insertion of LEU2 were ruled out in the tetrad 
analysis since AQT and LEU2 would follow the random assortment pattern instead of a 
2:2 segregation. The second scenario was that the loss of AQT was due to the deletion of 
AQT allele by the insertion cassette leaving only one copy of WT aqt gene in the 
potential (Figure 3.2B). Similar to the first category, the second sporulation should yield 
all tetrads of 2 Aqt+ Leu- : 2 Aqt- Leu+  with the exception that aqt was an essential gene, 
and deletion of it would cause inviability of the spores. If this was the case, the only two 
viable spores in the tetrads would be 2 Aqt+ Leu- spores. The inviability would not be 
seen in the first sporulation step because the sporulating culture was directly mated with 
haploid AQT strain without entering mitosis. Lastly, the possibility of the AQT allele 
Figure 3.2 Possible scenarios that  positive potentials may exhibit in tetrad analysis.
A – Insertion restores the WT copy of AQT.
B – Insertion deletes the mutant AQT.
























containing chromosome spontaneous arm loss cannot be excluded (Figure 3.2C). The 
insertion cassette was not linked with AQT in such a situation. The tetrad analysis would 
show either all tetrads of 2 viable Aqt+ spores or tetrads of 2 Leu+: 2 Leu- spores, however, 
Aqt+ and Leu+ were not linked to each other. Table 3.1 shows the summary of all 
potentials that have been tested according to this experimental strategy. 20 tetrads in total 
were dissected for each potential except for potential #25 (40 tetrads dissected). Only the 
full tetrads containing polyQ plasmid were analyzed through toxicity assay and tetrad 
analysis. In general, almost all insertion cassette follows the 2:2 segregation pattern, in 
which 2 His+ : 2 His- spores in each tetrad. However, Aqt+ frequently failed to give a 2:2 
segregation pattern which indicated the complication that many factors might be involved 
in polyglutamine cytotoxicity. 
 
Table 3.1 Tetrad analysis of Aqt- potentials after insertion of transposon mutagenesis 
library screening 






#23 10 PD 
NPD 
T 
2x(2Leu+Aqt-  : 2Leu-Aqt+) 
1x(2Leu+Aqt+  : 2Leu-Aqt-) 
6x(1Leu+Aqt+  : 1Leu-Aqt+ : 1Leu+Aqt-: 
1Leu-Aqt-) 
1x(2Leu+Aqt-  : 1Leu-Aqt+  : 1Leu-Aqt-) 
#25 17 PD 
NPD 
T 
1x(2Leu+Aqt-  : 2Leu-Aqt+) 
1x(2Leu+Aqt+  : 2Leu-Aqt-) 
2x(1Leu+Aqt+  : 1Leu-Aqt+ : 1Leu+Aqt-: 
1Leu-Aqt-) 
8x(2Leu-Aqt+  : 2Leu+Aqt+) 
3x(2Leu-Aqt+  : 1Leu+Aqt+: 1Leu+Aqt-) 
1x(2Leu+Aqt-: 1Leu-Aqt+: 1Leu-Aqt-) 
1x(2Leu+Aqt+: 1Leu-Aqt+: 1Leu-Aqt-) 
#26 7  2x(2Leu+Aqt-  : 2Leu-Aqt-) 
5x(2Leu+Aqt-: 1Leu-Aqt+: 1Leu-Aqt-) 
#29 16 NPD 1x(2Leu+Aqt+  : 2Leu-Aqt-) 
5x(2Leu+Aqt+  : 2Leu+Aqt-) 
4x(2Leu-Aqt+  : 2Leu-Aqt-) 
2x(2Leu+Aqt+: 1Leu+Aqt-: 1Leu-Aqt-) 
3x(2Leu+Aqt- : 1Leu+Aqt+  : 1Leu-Aqt+) 
1x(4Leu+Aqt-) 
#30 11  11x(2Leu+Aqt+ : 2Leu+Aqt-) 
#31 10 PD 
NPD 
T 
2x(2Leu+Aqt-  : 2Leu-Aqt+) 
1x(2Leu+Aqt+  : 2Leu-Aqt-) 
6x(1Leu+Aqt+  : 1Leu-Aqt+ : 1Leu+Aqt-: 
1Leu-Aqt-) 
1x(2Leu+Aqt-  : 1Leu-Aqt+ : 1Leu-Aqt-) 
#32 11 PD 
T 
2x(2Leu+Aqt-  : 2Leu-Aqt+) 
5x(1Leu+Aqt+  : 1Leu-Aqt+ : 1Leu+Aqt-: 
1Leu-Aqt-) 
1x(2Leu+Aqt- : Leu-Aqt- : Leu-Aqt+) 
1x(2Leu-Aqt- : Leu+Aqt- : Leu+Aqt+) 
2x(2Leu-Aqt- : Leu+Aqt- : Leu+Aqt+) 
#37 11 PD 
NPD 
T 
1x(2Leu+Aqt-  : 2Leu-Aqt+) 
4x(2Leu+Aqt+  :2Leu-Aqt-) 
5x(1Leu+Aqt+  : 1Leu-Aqt+ : 1Leu+Aqt-: 
1Leu-Aqt-) 
1x(2Leu+Aqt- : 1Leu-Aqt- : 1Leu-Aqt+) 
#39 9 NPD 1x(2Leu+Aqt+  : 2Leu-Aqt-) 
4x(2Leu-Aqt- : 2Leu-Aqt+) 
1x(2Leu+Aqt- : 1Leu+ Aqt+ : 1Leu-Aqt+) 
1x(2Leu+Aqt+ : 1Leu+ Aqt- : 1Leu- Aqt-) 
2x(2Leu+Aqt+ : 2Leu+Aqt-) 
#40 13 PD 1x(2Leu+Aqt-  : 2Leu-Aqt+) 
T 5x(1Leu+Aqt+  : 1Leu-Aqt+ : 1Leu+Aqt-: 
1Leu-Aqt-) 
2x(2Leu+Aqt- : 1Leu-Aqt+ : 1Leu-Aqt-) 
1x(2Leu-Aqt+ : Leu-Aqt- : Leu+Aqt-) 
1x(2Leu-Aqt- : Leu+Aqt+ : Leu+Aqt-) 
1x(2Leu+Aqt+ : Leu-Aqt- : Leu+Aqt-) 
1x(2Leu-Aqt- : Leu+Aqt- : Leu+Aqt-) 
1x(2Leu-Aqt- : Leu-Aqt+ : Leu+Aqt+) 
#43 7 PD 
NPD 
T 
2x(2Leu+Aqt-  : 2Leu-Aqt+) 
1x(2Leu+Aqt+  : 2Leu-Aqt-) 
4x(1Leu+Aqt+  : 1Leu-Aqt+ : 1Leu+Aqt-: 
1Leu-Aqt-) 
#44 10 PD 
T 
1x(2Leu+Aqt-  : 2Leu-Aqt+) 
4x(1Leu+Aqt+  : 1Leu-Aqt+ : 1Leu+Aqt-: 
1Leu-Aqt-) 
2x(2Leu+Aqt+ : 2Leu-Aqt+) 
2x(2Leu+Aqt+: 1Leu-Aqt+: 1Leu-Aqt-) 
1x(2Leu-Aqt-: 1Leu+Aqt-: 1Leu+Aqt+) 
#45 11 PD 
NPD 
T 
1x(2Leu+Aqt-  : 2Leu-Aqt+) 
2x(2Leu+Aqt+  : 2Leu-Aqt-) 
7x(1Leu+Aqt+  : 1Leu-Aqt+ : 1Leu+Aqt-: 
1Leu-Aqt-) 
1x(2Leu-Aqt-  : 1Leu+Aqt+ : 1Leu+Aqt-) 
#47 7 PD 
NPD 
T 
1x(2Leu+Aqt-  : 2Leu-Aqt+) 
4x(2Leu+Aqt+  :2Leu-Aqt-) 
1x(1Leu+Aqt+  : 1Leu-Aqt+ : 1Leu+Aqt-: 
1Leu-Aqt-) 
1x(2Leu+Aqt- : Leu-Aqt- : Leu-Aqt+) 
#48 12 PD 2x(2Leu+Aqt-  : 2Leu-Aqt+) 
7x(2Leu+Aqt+ : 2Leu+ Aqt-) 
2x(3Leu-Aqt- :1Leu-Aqt+) 
1x(2Leu-Aqt- :1Leu-Aqt+ : 1Leu+Aqt+) 
#49 10 PD 
NPD 
T 
1x(2Leu+Aqt-  : 2Leu-Aqt+) 
2x(2Leu+Aqt+  : 2Leu-Aqt-) 
4x(1Leu+Aqt+  : 1Leu-Aqt+ : 1Leu+Aqt-: 
1Leu-Aqt-) 
2x(1Leu+Aqt+  : 1Leu+Aqt-  : 2Leu-Aqt-) 
1x(2Leu+Aqt-  :2Leu-Aqt-) 
 
Centromere Linkage of AQT 
Interestingly, #47 potential exhibited a pattern of meiotic segregation, which was 
indicative of centromeric localization of both insertion and AQT (p < 0.01). To explore 
this further, we have disrupted each of the yeast genes met28, met3 and met14, linked to 
the centromeres of chromosomes IX, X and XI, respectively. Individual centromere 
linked gene was deleted using the plasmid containing a KanMX module (Longtine et al. 
1998). KanMX was amplified using primers with 40 bp homology and 20 bp 
complimentary to the plasmid by PCR as a 1.6kb fragment. This PCR product was gel 
purified and transformed into ubc4Δ aqt-wt haploid to delete one centromere linked gene. 
Taking MET3 gene for an example, MET3 locates closely to the centromere of 
chromosome X, and transformation of PCR amplified KanMX module replaced gene 
MET3 on chromosome X due to homologous recombination (Figure 3.3A). 
Transformants were plated on YPD for 1 day then velveteened onto G418 containing 
YPD. After 2-3 days, transformants that were resistant to G418 grew on the plate. Colony 
purified transformants were then confirmed by PCR (Figure 3.3B) and phenotypic assay 
(Figure 3.3C). Due the length difference between the WT gene and the KanMX module, 
PCR reactions using primers flanking the deletion locus to amplify a DNA fragment from 
the genomic DNA of deletion potentials was able to indicate whether the deletion was 
Figure 3.3 Construction of centromere-linked markers.
A – PCR-based gene deletion. Deletion cassette used for single gene deletions is PCR 
amplified from a plasmid bearing KanMX (gene for G418 resistance). Purified PCR 
fragment is transformed into yeast cells. Due to homologous recombination, gene to 
be deleted is replaced by the deletion cassette.
B – Identification of gene deletion by PCR. The example shown is identification of 
met3Δ. PCR is performed with genomic DNA using primers flanking the deletion 
locus. Correct deletion yields a 1.7kb PCR product, whereas the WT control is 2.3kb. 
The size difference enables the identification of deletion by PCR.
C – Identification of gene deletion by phenotypes. Given the example of MET3, 
which is involved in methionine synthesis, deletion does not grow on –Met medium, 
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successful. In the example shown in Figure 3, MET3 is longer than the deletion module, 
therefore a shorter fragment was amplified in a deletion potential as compared to the WT 
control (Figure 3.3B). Genes specifically selected for the centromere-linked gene deletion 
were all involved in amino acid biosynthetic pathways. Phenotypically, correct deletion 
was expected to grow on YPD containing G418 and to become auxotrophic for that 
specific pathway (Figure 3.3C). 
After both PCR and phenotypic assay confirmed the deletion to be correct, each 
deletion was crossed to the AQT strain, and resulting diploids, heterozygous by both AQT 
and respective deletion, were sporulated and dissected. If deletion and AQT are not linked 
to each other (on different chromosomes or distantly locate on the same chromosome) 
and AQT is not centromere linked, both deletion marker and AQT would follow random 
assortment, therefore tetratypes would be more frequently seen in such a case (Figure 
3.4A).If deletion and AQT are linked to each other, crossingovers happening in between 
of those two genes are less likely. Parental ditype (two spores represent one parental 
strain) would be the predominant type of tetrads seen this case (Figure 3.4B). All 
experiments were performed in the ubc4Δ [PIN+ PSI+] background, enabling us to 
monitor AQT by phenotype. One typical tetrad representing each type of tetrads from the 
cross of ubc4Δmet3Δ and ubc4Δ MET3 AQT was shown in Figure 3.4C. 
 As shown in Table 3.2, combination of each deletion with AQT produced 
primarily parental (PD) and nonparental (NPD) ditypes, but essentially no tetratypes (T) 
Figure 3.4 Centromeric linkage screening of AQT by tetrad analysis.
A and B – Strategy of locating AQT to a specific chromosome. Each strain with a 
specific centromere-linked marker is crossed to AQT strain of the opposite mating 
type. After sporulation and dissection, the predominant type of  tetrads will be 
tetratype if there’s no linkage between AQT  and that specific chromosome, and AQT 
is not centromere linked (A). If AQT is centromere linked and also linked to the 
marker, parental ditype will be the most abundant tetrad type (B).

















after sporulation and dissection. Apparently deletion and AQT did not follow the random 
assortment, which produces PD:NPD:T of 1:1:4 ratio. However, the approximately equal 
numbers of PD and NPD tetrads indicated the lack of linkage between AQT  and 
deletion. In summary, the tetrad analysis data suggested that AQT is located on a different 
chromosome from the respective deletion, but is linked to the centromere of its own 
chromosome (for explanation of tetrad types, see Sherman 2002).   
 
Table 3.2 Tetrad analysis of diploid AQT derivatives with individually labeled 
centromeres 










8x(2Met-Aqt-  : 2Met+Aqt+) 
7x(2Met+Aqt-  : 2Met-Aqt+) 






4x(2Met-Aqt-  : 2Met+Aqt+) 
6x(2Met+Aqt-  : 2Met-Aqt+) 
1x(1 Met+Aqt-: 1Met-Aqt+ : 1Met-Aqt- : 1 
Met+Aqt+) 





6x(2Met-Aqt-  : 2Met+Aqt+) 
6x(2Met+Aqt-  : 2Met-Aqt+) 
1x(2Met+Aqt-: 1Met-Aqt+ : 1Met-Aqt-) 
p< 0.01 for all three dissections. 
 
Detection of Chromosome II Disomy in AQT strains by Tetrad Analysis 
The next piece of information shedding light onto the molecular basis of AQT has 
come from the genetic cross in which the original AQT derivative, obtained in the strain 
bearing the ubc4∆::HIS3 disruption was crossed to the wild-type strain bearing the 
ubc4∆::KanMX disruption, made with the bacterial gene KanMX that causes resistance to 
the antibiotic G418 in yeast. Originally, the disruption made in the ubc4Δ aqt-wt was 
targeting HIS2 gene, which is linked to chromosome VI, with the same experimental 
procedure as deletions made in chromosome IX, X, XI. After sporulation and dissection, 
both AQT and KanMX markers segregated 2:2 as expected (Figure 3.5A). Surprisingly, 
majority of tetrads did show 3:1 or 4:0 segregation for the His+ phenotype, indicating that 
the KanMX might have gone to the ubc4 locus due to longer homology to the flanking 
sequence of the pre-existing HIS3 module from the same set of the plasmids for gene 
deletion, and there were two copies of the HIS3 allele in the AQT haploid. Notably, all 
AQT spores (76 total) obtained from tetrads with 2:2 ratio for KanMX were His+, and all 
His- spores were G418 sensitive and Aqt- (See Table 3.3 for tetrad analysis data). Large 
proportion of tetratype and low proportion of parental ditype indicated high frequency of 
meiotic trisomy chromosome pairing events in diploid yeast cells (Loidl 1995). PCR 
Figure 3.5 Discovery of chromosome II disomy in AQT strain.
A – Tetrad analysis showing unexpected segregation pattern. Tetrad analysis of a 
diploid obtained from mating of the AQT strain bearing the ubc4Δ::HIS3
transplacement, to the strain bearing the ubc4Δ::KanMX transplacement, 
demonstrates presence of at least 2 copies of HIS3 gene versus one copy of the 
KanMX gene. This can be concluded from the fact that majority of tetrads produce 
more than 2 His+ spores, in contrast to the typically 2:2 segregation by G418 
resistance caused by KanMX. All AQT spores in this cross were His+.
B – Confirmation of KanMX replacement of HIS3 at ubc4Δ locus by PCR. Due to the 
difference between KanMX module and HIS3 module, deletion potential is confirmed 
to bear ubc4Δ::KanMX instead of the original ubc4Δ::HIS3. 
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reactions amplifying the UBC4 gene confirmed that KanMX module replaced HIS3 
module in the deletion experiment (Figure 3.5B). 
 











3x(2 G418r His-Aqt-  : 2 G418s His+Aqt+) 
11x(2 G418s His+Aqt-  : 2 G418r His+Aqt+) 
22x(1 G418r His+Aqt+  : 1 G418s His+Aqt- : 1 
G418s His+Aqt+  : 1G418r His-Aqt-) 
1x(2G418r His+Aqt+  : 2G418s His+Aqt+) 
1x(1 G418r His+Aqt+  : 2 G418s His+Aqt- : 1G418r 
His-Aqt-) 
2x(1 G418s His+Aqt+  : 2 G418s His+Aqt- : 
1G418r His-Aqt+) 
 
The simplest scenario compatible with the ratios observed in the dissection and 
tetrad analysis is that AQT derivatives are disomics by chromosome II, containing the 
UBC4 gene (and respectively, the ubc4∆:: HIS3 disruption). As chromosome segregation 
is controlled by a centromere, such a scenario would also explain the centromere linkage 
of AQT. 
Confirmation of Chromosome II Disomy in AQT strains by Biochemical Techniques 
To better detect the presence of an extra chromosome, the pulse field gel 
electrophoresis was conducted. All three AQT isolates together with their isogenicWT 
strain was colony purified and two colonies were taken from each strain to be tested. 
Indeed, separation of the yeast chromosomes using the Bio-Rad CHEF (Contour-clamped 
Homogeneous Electric Field) gel electrophoresis apparatus was followed by Southern 
blotting to P32-labelled SSA3 DNA probes. The results confirmed that each of three 
independent AQT derivatives contained an additional copy of the chromosome II band 
(Figure 3.6A). Unexpectedly, electrophoretic mobilities of duplicated chromosomes 
varied among AQT derivatives, and in the case of AQT isolate #2, the difference was 
detected between two isolates of one and the same AQT derivative.  
Additionally, two tetrads from dissection of diploid heterozygous by AQT were 
also performed the pulse field gel electrophoresis and Southern blotting experiment 
described above. The parental strains were used as the controls, and two colonies were 
tested. Since all Aqt+ spores showed two bands for chromosome II, apparently the 
extra-copy of chromosome II also co-segregated with AQT in tetrad analysis (Figure 
3.6B). The variations in electrophoretic mobilities of chromosome II copies were also 
detected. 
In order to detect whether there was fragment loss or duplication of chromosome 
II in AQT isolates, which may potentially explain the variability in the electrophoretic 
mobility, the Comparative Genomic Hybridization (CGH) assay was performed. 
Figure 3.6 Confirmation of chromosome II disomy in AQT strain and derivatives by 
PFGE.
A – PFGE and Southern blotting of WT and AQT isolates. Chromosome fractionation 
by PFGE (left), followed by Southern blotting (right) demonstrates the presence of the 
extra copy of chromosome II in all AQT derivatives. Chromosome II bands are 
indicated by arrows on the CHEF gel, and visualized by hybridization to the labeled 
fragment of SSA3 gene (located on chromosome II) on Southern blot. Per each 
independent AQT derivative (designated as AQT2, AQT7 and AQT9) and wild-type 
control (WT), two isolates are tested. Note variation in chromosome II electrophoretic
mobilities (see text for comments).
B – PFGE and Southern blotting of  segregants from AQT heterozygous diploids. Two 
tetrads from dissection of diploid heterozygous by AQT/aqt-wt are tested together 
with the respective parental haploid strains. As indicated by arrows and the intensity 
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However, the DNA microarray-based analysis confirmed that all AQT derivatives 
contained an extra copy of every piece of the coding material in chromosome II (Figure 
3.7A, for CGH raw data, see APPENDIX B). This suggests that either variations in 
electrophoretic mobility are due to repetitive non-coding elements, or they reflect 
exchanges of material between non-homologous chromosomes.  
Conclusions 
Instead of a mutation in a single genetic locus as previously characterized, both 
classic genetic analysis and biochemistry based genome analysis data demonstrate that 
AQT is associated with an extra copy of chromosome II. 
Figure 3.7 Confirmation of chromosome II disomy in AQT strain and derivatives by 
DNA microarray analysis.
A – CLAC consensus plot of AQT derivatives. Hybridization to a complete DNA 
microarray of the S. cerevisiae genome confirms that all the coding material of 
chromosome II is duplicated in the AQT strains. Comparison is performed using 
CGH-Miner.
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IDENTIFICATION OF SUP45 AS A GENE RESPONSIBLE FOR AQT 
 
Materials and Methods 
Strains and Plasmids 
AQT isolate #7 (GT574) was used in the serial deletion analysis identifying the 
gene responsible for AQT effects. The WT control strain was the isogenic ubc4Δ strain 
(GT349) in which the independent AQT isolates were derived from.  
Plasmid pGSHU carrying a cassette containing the orthologous URA3 gene from 
Kluyveromyces lactis and hygromycin resistant gene hygr as selectable/counter-selectable 
markers was used to insert into the extra chromosome II set points (Storici and Resnick 
2006). Further deletions were conducted using a LEU2 gene from plasmid vector pRS315 
(Sikorski and Hieter 1989) as the selectable marker. 
Methods 
Deletion primers were generally 70 bp long, which consist of 50 bp homology to 
flank the sequence to be deleted and 20 bp complementary to ends of marker genes to be 
PCR amplified. Determination of the 50 by homology sequences were based on the 
BLAST search in SGD database aiming at a minimal number of homology within the 
genome. By doing this, the efficiency of homology recombination based DNA 
replacement was increased. 
Phusion High Fidelity PCR Master Mix (manufactured by New England BioLabs) 
was used to amplify the KlURA3-hygr cassette from the plasmid pGSHU and genomic 
DNA of deletion potentials. 
Results 
Serial Deletion Analysis of Chromosome II Extra Copy 
With previous demonstrated chromosome II disomy in the AQT strain which was 
the cause of AQT effects, a hypothesis was proposed that a specific gene or few genes 
were responsible for the decreased polyglutamine toxicity in AQT strains. Base on the 
well developed PCR-based genomic DNA manipulation approaches, we decided to delete 
chromosomal fragments within the extra chromosome II in a serial division fashion to 
look for the gene responsible for the Aqt+ phenotype.  
One first step in the serial deletion analysis involved the insertion of the 
KlURA3-hygr cassette from pGSHU for selection/counter-selection into the set points. 
The set point for chromosome II left arm was at 190234-190383 (inside gene PEP1, 48kb 
from centromere) (Figure 4.1A). The set point for chromosome II right arm was at 
519000-519449 (inside gene IRA1). Taking the chromosomal left arm deletion as an 
example, the KlURA3-hygr cassette from pGSHU was amplified and gel purified prior to 
Figure 4.1 Illustration of serial deletion analysis.
A – Schematic view of fragment deletion with selectable markers. Deletion of region 
3 (Rg3) on the extra chromosome II is shown as an example. The first step of deletion 
employs the insertion of selectable/counter-selectable markers from plasmid pGSHU, 
which contains KlURA3 and hygr genes. The KlURA3-hygr cassette together with the 
target region is replaced by transformation of DNA fragment of LEU2 gene and 














transforming into the AQT haploid strain. KlURA3 and hygrgenes served as selectable 
markers in this step. The 2kb fragment containing LEU2 gene amplified from vector 
pRS315 was then used to replace the large fragment including the KlURA3-hygr cassette 
inserted in the first step. The lost of resistance to hygromycin, auxotrophy of Uracil, and 
the prototrophy of Leucine indicated the replacement of KlURA3-hygr cassette by LEU2 
and the deletion in the extra chromosome II was achieved (Figure 4.1A). In addition to 
the phenotypic assay on plates selecting for the presence or absence of antibiotic resistant 
genes and auxotrophic markers, PCR reactions were conducted to confirm both insertion 
of the KlURA3-hygr cassette (Figure 4.2) and replacement by LEU2 gene (Figure 4.3). To 
confirm the proper insertion of the KlURA3-hygr cassette, 3 PCR reactions were designed 
in the way that not only the insertion position was confirmed, but the presence of an 
unchanged chromosome II was also tested. The relative positions and directions of 
primers were shown in Figure 4.2A. Primers URA3.1 and SCE.2 were inside the 
KlURA3-hygr cassette, and primers ChkPL5’ and ChkPL3’ were outside of the insertion 
region. Only the correct insertions gave the expected length of DNA fragment for the 
PCR reactions locating the insertion position (Figure 4.2B). Primer pair ChkPL5’/3’ was 
able to amplify the unmodified region from both the extra chromosome II of the insertion 
potential (I) and the chromosome II of the wild type control (WT).  
Confirmation of the proper deletion of the large fragment of chromosome II 
followed a similar way of PCR design (Figure 4.3 A and B) after the screening process 
Figure 4.2 Confirmation of cassette insertion.
A – Schematic view of primers positions. A set of six primers are used to confirm the 
KlURA3-hygr cassette (pGSHU) insertion. PCR reactions using primer pairs 
ChkPL5’/URA3.1 and SCE.2/ChkPL3’ are conducted to ensure the correct insertion 
location of the KlURA3-hygr cassette. Primer pair ChkPL5’/ChkPL3’ are used to 
detect the presence of the other non-modified chromosome II.
B – PCR identification of insertion. PCR reactions were performed using 3 pairs of 















Figure 4.3 Confirmation of cassette proper deletion.
A – Schematic view of primers positions. Similar to the strategy of confirming 
KlURA3-hygr cassette insertion, proper deletion by LEU2 deletion allele involves 3 
PCR reactions.
B – PCR identification of deletion. All bands are of expected sizes.
C – Plate polyglutamine toxicity assay of region 1-3 deletions. Deletion of Rg2 



































on plates. Due to the length of the target regions, deletion efficiency was significantly 
affected. Table 4.1 is the summary of deletion potentials obtained throughout the deletion 
identification process. 
 












Region 1 974 974 15 1 
Region 2 1200 1200 9 4 
Region 3 2220 2220 8 2 
 
The toxicity assay of AQT strain with Region 1, 2, and 3 individually deletion 
revealed that the gene responsible for AQT effects resided in Region 2 (Figure 4.3C). 
Deletion of SUP45 Gene Eliminates AQT Effects in [PSI+] Background 
As the serial deletion analysis confined AQT to the region of the chromosome II 
right arm, located between the positions 518877 and 779754 (Region 2) (Figure 4.4A), 
more extensive and detailing deletions were then made to this region. Utilizing the 
pre-existing set point, subregional Rg 2.1 and Rg 2.2 deletions were made. Both deletions 
were able to eliminate the AQT effect on polyQ toxicity, indicating the shorter region of 
Figure 4.4 Identification of SUP45 as a gene responsible for AQT in the [PSI+] 
background.
A – Sequential deletion mapping of the chromosome II extra copy in the AQT strain.  
The AQT7 derivative No. 7 was used in these experiments. Each numbered region 
corresponds to a respective deletion. Deletions eliminating the antitoxicity phenotype 
in the [PSI+] background are shown as yellow boxes. All deletions were verified by 
PCR. Five ORFs located within the region 2.1a were each deleted individually; among 
those deletions, only deletion of SUP45 eliminated AQT as shown on panels B and C.
B and C – Elimination of the antitoxic effect on 103Q (B) and 103QP (C) by the 























interest was from 518877-610753. Consequently, Rg 2.1 was divided into 5 smaller 
pieces, Rg 2.1a- Rg2.1e. Region 2.1a deletion, from 518877 to 545266 showing the Aqt- 
phenotype was further analyzed until the search by serial deletions reached the region of 
5 ORFs, including essential gene SUP45. Product of this gene, named Sup45 or eRF1, is 
a translation termination factor, working together with Sup35 (eRF3) (Stansfield et al. 
1995). Individual ORF deletions were made within this region (from 528161 to 537490). 
Deletion of the extra copy of SUP45 gene, located on the duplicated chromosome II in 
the AQT strain, eliminated the anti-toxicity effect on both 103Q (Figure 4.4B) and 103QP 
(Figure 4.4C). 
Other Phenotypes Associated with Extra Copy of Chromosome II are Independent 
on SUP45 
While sup45 deletion eliminated amelioration of polyglutamine toxicity in the 
[PSI+] AQT ubc4Δ strain, it has not influenced amelioration of temperature sensitivity 
(see Figure 4.5A). WT, AQT, and AQT with sup45Δ strains were grew in YPD for 1 day, 
then counted by hemacytometer to determine the cell concentration of each sample. Cell 
concentrations were then equilibrated according to the cell counts, and serial decimal 
dilution was conducted for each sample prior to the transfer to YPD plates by an 
8-channel pipettor. Duplicated YPD plates were incubated at 30°C and 39°C, respectively, 
for 2 days. The temperature sensitivity eliminated by AQT did not recover in the AQT 
strain with sup45 deletion (Figure 4.5A). 
In addition to the characteristics of AQT strain, such as temperature resistance at 
39°C and anti-Sup35 toxicity effect, the ability to invade agar was observed in both wild 
type and ubc4∆ strains, but not in AQT strain. Deletion of sup45 in AQT strain did not 
affect the loss of agar invading capability (Figure 4.5B). 
These data (Figure 4.5) indicate that some phenotypes, associated with the 
chromosome II disomy, are caused by extra dosage of some other gene(s), located on 
chromosome II instead of SUP45. 
Conclusions 
The strategy of making serial deletions in the extra chromosome II looking for the 
gene responsible for AQT effect on the polyglutamine toxicity succeeded after at least 5 
rounds of deletion and toxicity assay. Large quantities of deletion potentials were 
screened to identify the correct deletion. 
Even with the ability to from aggresome, 103QP still caused toxicity in the [PIN+ 
PSI+] prion background. The ability of sup45Δ in AQT strain to eliminate the 
anti-polyglutamine toxicity for both 103Q and 103QP indicated the shared mechanism or 
pathway of 103Q and 103QP toxicity in the [PIN+ PSI+] cells. 
Figure 4.5 SUP45 independent phenotypes associated with chromosome II disomy.
A – Temperature resistance at 39°C in AQT  strain was not affected by sup45 
deletion. Serial of decimal dilution was made in 96-well plates. Multi-channel 
pipetteor was used to transfer 5μl of culture to place onto YPD plates. Two identical 
plates were incubated at either 30°C or 39°C for two days before the plates were 
scanned.
B – The invasive phenotype of the wild-type and ubc4Δ strains was eliminated by 
AQT. However, deletion of sup45 doesn’t affect the phenotype of lack of agar 
invasion. Cells were patched on a YPD plate and incubated at 30°C for 2 days. The 




















Some characteristics of AQT strains, at least the temperature resistance and the 
loss of agar invading ability, are associated with chromosome II disomy, indicating the 




ROLE OF RELEASE FACTORS IN [PSI+]-DEPENDENT 
POLYGLUTAMINE TOXICITY 
 
Materials and Methods 
Strains and Plasmids 
WT UBC4+ strain used in this study was GT81-1C. The AQT UBC4+ strain 
(segregant GT1665-3A) was obtained from dissection of GT1665, which was made by 
crossing GT81-1D with GT574 (AQT isolate #7). Since all AQT isolates were 
ubc4Δ::HIS3, the AQT UBC4+ segregant was isolated from the tetrads of all 4 His+ spores, 
resulting the presence of one allele of WT UBC4 and one allele of ubc4Δ::HIS3. The 
heterozygosity of UBC4/ubc4Δ in the AQT UBC4+ haploid strain was confirmed by PCR. 
GT574 was used as the AQT strain and GT349 was the respective WT ubc4Δ control. 
The SUP45 plasmid constructs included the centromeric plasmids bearing wild 
type or mutant (sup45-103) alleles of SUP45 gene under its endogenous promoter (a gift 
of G. Zhouravleva); plasmid CEN-SUP45ΔC19, bearing the deletion of 19 C-terminal 
codons in SUP45 (a gift of D. Bedwell); the centromeric plasmid bearing the SUP45ΔC5 
allele that lacks 5 C-terminal codons and causes only slight impairment of Sup45 
function; the galactose-inducible SUP45 plasmid, containing the SUP45 cDNA under the 
control of GAL1 promoter. The CEN-SUP35C plasmid contained the SUP35C region 
under the endogenous SUP35 promoter. Plasmid pCUP-Sup35NM-DsRed overexpressed 
Sup35NM domain and red fluorescent protein under the control of CUP1 promoter. The 
plasmid overexpressing UBC4 was a gift of M. Hochstrasser. Plasmids for the 
β-galactosidase assay were a gift of M. Tuite. 
Methods 
SDS-PAGE experiments were all done in the 10% acrylamide gel with 0.1% SDS. 
The amount of total protein loaded was equalized for all samples according to the 
Bradford assay, and confirmed by loading control protein Ade2p or Coomassie staining.  
SDD-AGE experiments were done following the standard protocol (Halfmann 
and Lindquist 2008) with minor modifications. The capillary transfer stack was 
assembled from bottom to top: 9 pieces of thick blotting paper, 4 pieces of thin blotting 
paper, 1 piece of pre-wet thin blotting paper, the nitrocellulose membrane, agarose gel, 3 
pieces of pre-wet thin blotting paper, the wick (3 pieces of wide pre-wet thin blotting 
paper), 1 pieces of pre-wet thin blotting paper, agarose gel casting tray and a bottle of 200 
ml water. 
For fluorescent microscopy experiments including the immunofluorescent 
microscopy, see Chapter 2 Methods.  
Results 
Level of Sup45p is Increased in AQT Strain 
As discussed in Chapter 4, SUP45 was identified as the gene responsible for AQT 
effect. We decided to further analyze the levels of Sup45p in the AQT strain. Western 
blot was performed to protein total lysate isolated from haploid AQT strain and the 
isogenic WT as control. Ade2 protein served as the loading control. Western blot analysis 
confirmed that the AQT derivative contains more Sup45 protein, compared to the 
isogenic wild type strain (Figure 5.1A). Moreover, when compared between UBC4+ and 
ubc4Δ background, the increase of Sup45p level was more profound in ubc4∆ 
background (Figure 5.1 B), which is 2.5 fold as opposed to 1.5 fold in the UBC4+. Thus, 
presence of the extra-copy of SUP45 gene leads to increased levels of Sup45 protein in a 
partly ubc4∆-dependent fashion, and is responsible for the anti-toxic (Aqt+) phenotype in 
the [PSI+] background. 
Increased Expression of Sup45p in WT and Ubc4Δ Strains Leads to Decreased 
PolyQ/QP Toxicity 
Next, we tested if increase in the Sup45 levels, produced by the means other than 
duplication of chromosome II, would also ameliorate the [PSI+]-dependent polyglutamine 
toxicity. Indeed, introduction of the centromeric plasmid bearing the SUP45 gene under 
its own (Figure 5.2A) or galactose-inducible (Figure 5.2B) promoter (in a latter case, 
under inducing conditions) ameliorated toxicity of both 103Q and 103QP. Anti-toxic 
Figure 5.1 Level of Sup45p is increased in AQT strains.
A – Levels of Sup45 protein are elevated in AQT ubc4Δ strain, compared to WT 
ubc4Δ strain (Ade2 protein is used as the loading control).
B – Increase in Sup45 protein levels is more profound in the AQT ubc4Δ strain, 
compared to the isogenic AQT strain, bearing the wild type UBC4 gene (UBC4+) on 
one of the copies of chromosome II. 
C – Bar graph of Sup45p level is shown relative to the isogenic non-AQT control in 
both UBC4+and ubc4Δ backgrounds. At least 3 measurements with independent 




































Figure 5.2 Modulation of polyglutamine toxicity by the plasmid-borne release factor 
genes.
A and B – Plasmid-borne extra copy of SUP45 gene under endogenous (A) or 
galactose-inducible PGAL (B)  ameliorates toxicity of 103Q and 103QP in both  wild 
type (WT) and ubc4Δ [PSI+] strains.
C and D – Centromeric plasmids with SUP45 gene under endogenous (C) or 
galactose-inducible PGAL (D) promoters increase levels of Sup45 protein in both wild 
type (WT) and ubc4Δ strains. Cultures were grown in liquid -Ura -Leu glucose (C) or 
-Ura -Leu galactose/raffinose (D) medium. Ade2 protein is shown as a loading 
control.
E – Expression of the Sup35 derivative lacking the prion and middle domains 
(Sup35C) decreases 103Q and 103QP toxicity in both wild type (WT) and ubc4Δ


































ubc4Δ ubc4Δ ubc4Δ ubc4ΔUBC4+ UBC4+ UBC4+ UBC4+
CEN-SUP45 GAL1-SUP45+ + + +----
effect of plasmid-borne SUP45 was clearly detected in both ubc4Δ and UBC4+ 
backgrounds, indicating that it was less sensitive to the presence of Ubc4 protein, 
compared to the chromosomal extra copy. For both plasmids, Sup45 overproduction was 
confirmed by protein analysis (Figure 5.2C and D). 
Overexpression of Sup35C Decreases PolyQ/QP Toxicity 
Remarkably, when an extra copy of the altered SUP35 gene, coding for the Sup35 
protein that lacks the N-terminal (prion) and middle domains and is therefore unable to be 
incorporated into the [PSI+] prion aggregates (SUP35C) was introduced into the cells, the 
polyglutamine toxicity of both 103Q and 103QP in the [PSI+] strain was also ameliorated 
(Figure 5.2E). 
Function of Sup45p is Required for AQT Effect 
However, antitoxicity caused by a centromeric plasmid bearing the SUP45 
derivative (SUP45ΔC5), that is missing the C-terminal 5 amino acids but remains 
functional (Chernoff et al. 1992), was partially dependent on ubc4Δ  (Figure 5.3A). 
Ability of the extra-copy of SUP45 to ameliorate polyglutamine toxicity was abolished 
by a deletion of 19 C-terminal amino acids (Figure 5.3B), that impairs Sup45 function in 
translation and interaction with Sup35 (Kallmeyer et al. 2006), or by the missense 
mutation sup45-103, T62C (Figure 5.3C) that also impairs Sup45 function in translation 
Figure 5.3 Functionally impaired Sup45 is not able to cause AQT effect.
A – Plasmid expressing the SUP45 allele with a short C-terminal deletion, SUP45ΔC5 
(that only slightly impairs Sup45 protein function) from the endogenous SUP45
promoter, ameliorates 103Q and 103QP toxicity in partially ubc4Δ-dependent fashion.
B and C – Plasmids, expressing the SUP45 alleles with either a longer C-terminal 
deletion, SUP45ΔC19 (that abolishes Sup45 function and interaction with Sup35) (B) 
or missense mutation sup45-103, T62C (that impairs Sup45 function) (C) from the 
endogenous SUP45 promoter, do not ameliorate 103Q and 103QP toxicity.
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termination (Moskalenko et al. 2004). Thus, Sup45 ability to ameliorate toxicity depends 
on the same sequence elements that control its function in translational machinery. 
Aggregation Pattern of Sup35 and PolyQ/QP in AQT Strain  
As both polyglutamines and prion form of Sup35 form SDS-resistant polymers in 
the yeast cells, we have checked if patterns of their aggregation are influenced by the 
presence of an extra copy of SUP45. Both 103Q and 103QP proteins exhibit a broad 
range of distribution of the SDS-resistant polymers by size, as demonstrated by 
semi-denaturing agarose gel electrophoresis (SDD-AGE), with 103QP containing more 
protein in the higher molecular weight (MW) fraction (Figure 5.4A). This result confirms 
that aggresome, formed by 103QP, contains insoluble protein aggregates, in contrast to 
the juxtanuclear quality control compartment (JUNQ) observed in the yeast cells with the 
defect of ubiquitin-proteasome system (Bagola and Sommer 2008). Neither 103Q nor 
103QP polymer distribution was significantly affected by AQT (Figure 5.4A). In the wild 
type [PSI+] cells, lacking 103Q or 103QP, Sup35 prion polymers were distributed within 
a narrower range of sizes, compared to polyglutamines (Figure 5.4B). However, in the 
presence of either 103Q or 103QP, size range of the Sup35 polymers was increased and 
higher MW polymers were accumulated, suggesting that some Sup35 could be associated 
with 103Q (or 103QP) polymers, therefore partly following their distribution. Notably, 
the range of the Sup35 polymer size distribution became narrower in the presence of AQT, 
Figure 5.4 Polymer fractionation assay by SDD-AGE.
A and B – Fractionation of the polyQ/QP-GFP (A) and Sup35 (B) polymers by sizes 
in the ubc4Δ [PSI+] strains either with (AQT) or without (WT) AQT. Polymers were 
separated by SDD-AGE (see Chapter 2 Methods). Filter obtained from one and the 
same gel was reacted to either GFP (A) or Sup35C (B) antibodies. Ployglutamines
alter distribution of Sup35 ploymers, and this effect is counteracted by AQT. 
Experiment has been repeated with 3 independent cultures per each combination, each 
time with the same result.
C – No Sup45 polymers were detected by SDD-AGE.

















and the high MW fraction, which depends on 103Q/QP, disappeared (Figure 5.4B). This 
suggests that extra dosage of Sup45 somewhat counteracts increase in size of Sup35 
polymers and possibly, their interaction with polyglutamines. As expected, Sup45 protein 
itself does not convert into the SDS-resistant polymers (Figure 5.4C). An additional piece 
of information on lack of SDS-resistant polymers of Sup45p was obtained from western 
blot. Length of 2% SDS treatment and pre-loading sample boiling didn’t not affect the 
solubility of Sup45p in SDS-PAGE (Figure 5.4D). 
Colocalization of Sup35/Sup35NM Aggregates and PolyQ/QP 
Immunofluorescence microscopy data show that while most of the cytologically 
detected Sup35 aggregates are distinct from 103Q (or 103QP) aggregates, colocalization 
of some Sup35 with 103Q or 103QP was detected in essentially every cell containing 
both types of aggregates in both WT and AQT strains (Figure 5.5A). Unexpectedly, 
Sup45 was also observed as aggregates similar to the sizes and distribution of those 
Sup35 aggregates in the immunofluorescence microscopy. Partial colocalization of Sup45 
with 103Q or 103QP was also detected the same as for Sup35 (Figure 5.5B), which was 
very likely due to the presence of interaction between Sup35 and Sup45 instead of Sup45 
aggregates. When Sup35NM, tagged with DsRed, was overproduced in the [PSI+] strain 
also expressing 103QP, most of Sup35 was eventually assembled into one large deposit, 
either partially or completely overlapping with the 103QP aggresome (Figure 5.5C). 
Figure 5.5 Colocalization of [PSI+] and polyglutamines.
A – Some (but not all) of Sup35 aggregates, visualized by secondary 
immunofluorescence (red) in the ubc4Δ [PSI+] strain, colocalize with 103Q or 103QP 
aggregates, visualized by GFP tag (green).
B – Sup45, seen in aggregates (red) in the ubc4Δ [PSI+] strain in immunofluorescence 
microscopy, partially colocalize with 103Q or 103QP .
C – Overexpressed Sup35NM-DsRed (red) forms large clumps in the [PSI+] cells, that 




















Moreover, this sequestration was not affected by an extra copy of SUP45 (Figure 5.5C 
and Table 5.1), however, it was expected, as Sup35NM-DsRed construct does not contain 
a major region of interaction with Sup45, located within Sup35C (Wang et al. 2001). 
 
Table 5.1 Summary table of colocalization of Sup35NM and 103QP aggregates 
Sample Overlapped Partial Overlapped Distant Total 
AQT No.1 24 11 7 42 
AQT No.2 30 8 5 43 
WT No.1 26 8 7 41 
WT No.2 28 8 12 48 
Two independent colonies were taken from AQT and WT strains for the 
colocalization detection, respectively. There was no significant difference between AQT 
and WT. 
 
Effects of Polyglutamines and AQT on Sup35 and Sup45 Aggregation 
We have also checked effects of polyglutamines and gene dosage on patterns of 
Sup45 aggregation. Sequestration of Sup45 by the Sup35 prion aggregates is known to 
contribute to cytotoxicity of overproduced Sup35 in [PSI+] strains (Vishveshwara et al. 
2009). Although we could not detect aggregate-associated Sup45 by SDD-AGE (Figure 
5.4C), apparently because it is not converted into an amyloid form and is therefore 
released after SDS treatment (Figure 5.4D), centrifugation analysis demonstrates that 
presence of either [PSI+] prion or 103Q protein results in the shift of a fraction of Sup45 
protein to the pelletable (aggregate-associated) form, with both factors together having an 
additive effect (Figure 5.6A). Effect of 103Q in the [psi-] strain is probably mediated by 
its ability to promote aggregation of Sup35 even in a non-prion form, as reported 
previously (Urakov et al. 2010) and confirmed by us (Figure 5.6A). 103QP did not 
exhibit any observable effect on Sup45 aggregation on its own. However, it promoted 
Sup35 aggregation in [psi-] and further increased Sup45 aggregation in the presence of 
[PSI+]. Remarkably, proportion of the pelletable versus soluble Sup45 was decreased in 
the AQT (disomic) [PSI+] strain expressing 103Q or 103QP, compared to the identical 
strain not possessing disomy (Figure 5.6B). This shows that increase in level of Sup45 
counteracts its sequestration by aggregates. 
Termination Readthrough in the Strains Expressing Polyglutamines 
As our data point to sequestration of release factors as a mechanism of 
polyglutamine toxicity, we have checked if polyglutamines increase translational 
readthrough of stop codons. For this purpose, the chimeric constructs bearing a stop 
codon between the PGK1 and lacZ ORFs have been employed. Surprisingly, no increase 
Figure 5.6 Modulation of polyglutamine toxicity by the plasmid-borne release factor 
genes.
A – Expression of 103Q promotes aggregation of Sup35 and Sup45, whereas 
expression of 103QP promotes only Sup35, in the ubc4Δ [psi-] strain, and increases 
aggregate-associated fraction of Sup45 in the ubc4Δ [PSI+] strain, as detected by an 
increase in the pellet (P) versus supernatant (S) fraction in comparison to the 
respective strain expressing 25Q, as determined by centrifugation analysis, followed 
by Western blotting.
B – Proportion of soluble (supernatant, S) versus aggregate-associated (pellet, P) 
Sup45 is significantly increased in AQT ubc4Δ [PSI+] strain, compared to the identical 
non-AQT (WT) strain, as determined by centrifugation analysis, followed by Western 
blotting.
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in translational readthrough (measured by β-galactosidase activity) has been detected in 
the presence of 103Q (Table 5.2).  
 
Table 5.2. Readthrough of stop codon UGA in the absence and presence of 103Q. 
PolyQ Readthrough (%) 
25Q 0.43 ± 0.07 
103Q 0.32 ± 0.15 
Cultures were grown in -Ura -Trp glucose medium to reach early stationary phase. Cells 
were washed 3 times before being transferred to -Ura -Trp glactose/raffinose medium for 
24 hours induction. Three independent cultures were tested. p> 0.05. 
 
These data suggest that either damage to translational machinery, caused by the 
aggregation and sequestration of release factors in the presence of polyglutamines, is so 
severe that translation is arrested and not proceeding beyond the stop codon, or 
cytotoxicity is related to non-translational functions of release factors (see Discussion for 
more detail). 
Discussion 
Amelioration of [PSI+]-dependent cytotoxicity by expression of the 
non-prionogenic derivative of Sup35 (Sup35C), or by extra-dosage of the Sup35 
functional partner, Sup45, indicates that toxicity results from sequestration of release 
factor(s) by polyglutamine aggregates. Possibly Sup35, containing QN-rich domain, is 
sequestered directly, while Sup45 is sequestered via its interaction with Sup35. Indeed, 
ability of polyglutamines to facilitate aggregation of endogenous QN-rich proteins even 
in a non-prion strain has been reported previously (Derkatch et al. 2004; Urakov et al. 
2010), and it was shown that Sup35 prion aggregates cause toxicity via sequestering 
Sup45 when Sup35 is overproduced at high levels in the [PSI+] strain (Vishveshwara et al. 
2009). In agreement with these data, AQT (i. e., extra copy of SUP45) ameliorates both 
polyglutamine toxicity and toxicity of excess Sup35 in the [PSI+] cells.  There is 
probably a competition for Sup35/Sup45 complex between polyglutamine aggregates and 
functional sites at which Sp35/Sup45 complex is supposed to act,, therefore increased 
abundance of Sup45, for example in result of disomy by the chromosome containing a 
respective gene (as in AQT derivatives), not only increases a proportion of 
non-sequestered Sup45 but also partly counteracts sequestration of Sup35, that can be 
seen as a change in size distribution of the Sup35 polymers. Hence this is the antitoxic 
effect of excess Sup45. 
On surface, two observations contradict such a simplistic model. First, in the cells 
that do not overproduce Sup35, only a small fraction of Sup35 aggregates are colocalized 
with cytologically detectable polyglutamine aggregates, and this colocalization is not 
completely abolished in the AQT strain (Figure 5.5A). However, we don’t know which 
fraction of Sup35 remains functional in the [PSI+] strains. Although it is clear that some 
fraction should retain function, as Sup35 is an essential protein and its complete 
elimination is lethal (Dagkesamanskaya and Ter-Avanesyan 1991), it remains unknown 
whether functional component is represented by the residual non-aggregated Sup35, 
smaller oligomers, or both. If functional Sup35 constitutes only a small fraction of total 
Sup35 protein in the [PSI+] cells, sequestration of this fraction by polyglutamines and its 
release in the presence of excess Sup45 would be difficult to detect cytologically, but 
these changes would still have profound physiological consequences. At least, change in 
the distribution of Sup35 polymers by size in the presence of polyglutamines, which is 
reversed in the strains bearing extra-copy of SUP45 (Figure 5.4B), clearly shows that 
certain alterations of Sup35 aggregation patterns, making them less similar to polyQ 
aggregation patterns, coincide with the antitoxic phenotype. 
Another complication is that sequestration of release factors by polyglutamines 
does not appear to further increase the stop codon readthrough in the [PSI+] cells (Table 
5.2). One possibility is that complete absence of release factors from the translational 
machinery damages it to such an extent that not only termination but also translation 
through the stop codon becomes impossible. Another possibility is that toxicity is related 
to non-translational functions of Sup35/45. Indeed, it has been reported that the 
immediate consequence of the severe shortage of a release factor in yeast is a 
cytoskeleton defect leading to cell death (Valouev et al. 2002). 
Relevance of yeast data to human polyglutamine disorders.  
Involvement of translational machinery in HD has been suspected from some 
results in mammalian systems (King et al. 2008). It remains unknown if polyglutamines 
can sequester the human homologs of Sup35 and Sup45 (respectively, eRF3 and eRF1), 
as mammalian ortholog of Sup35, eRF3, does not have a QN-rich domain. However, our 
results could be relevant to mammalian systems in a more general way. About 40% of 
variation in the age of HD onset in case of the same length of polyglutamine repeat is due 
to genetic variation (Wexler et al. 2004). Our work provides potential explanation for 
such a variation by demonstrating that changes in the abundance of the sequestered 
protein(s), occurring via alteration of either gene dosage or gene expression, can 
modulate polyglutamine toxicity. Non-genetic component of variations in polyglutamine 
toxicity can be explained by differences in the composition of other aggregated proteins 
(e. g. endogenous self-perpetuating aggregates or prions) present in the cell. Our results 
show that prion composition of the cell not only drives polyglutamine toxicity but also 
determines a pathway via which polyglutamines influence cell physiology, as proteins 
already associated with the other aggregates are more likely to be sequestered by 
polyglutamines. Mammalian cells contain a variety of proteins with the prion-like 
QN-rich domains, and machinery for propagation of the QN-rich protein aggregates 
exists in mammals. It is entirely possible that either organisms or tissues (or both) differ 
by the aggregate composition, and this in turn influences their susceptibility to 
polyglutamine disorders. Composition of endogenous aggregates may also modulate 
which proteins are sequestered by polyglutamines, as proteins associated with other 
QN-rich aggregates are more likely to be sequestered, like Sup45 in the cells containing 
the Sup35 prion. This could explain why different groups are coming out with different 
conclusions in regard to both mechanisms of polyglutamine toxicity and contributions of 
different types of polyglutamine aggregates. 
Conclusions 
Levels of Sup45p in UB4+ and ubc4Δ WT strains are indeed increased due to the 
increased dosage of SUP45. However, presence of WT UBC4+ controls the level of 
Sup45 in a more stringent way, resulting in a less profound increase of Sup45p as 
compared to that in ubc4Δ background. 
Excess of the termination factor Sup45 or presence of non-prion derivative of the 
termination factor Sup35 (Sup35C) ameliorates polyQ/QP toxicity. 
Function of Sup45, including stop codon recognition and ability to interact with 
Sup35, is required for ameliorating polyQ/QP toxicity. 
Pattern of polyQ/QP polymer distribution is not affected by AQT. 
Presence of polyQ/QP polymer broadens the range of sizes of Sup35 polymer, 
indicating the sequestration of Sup35 by polyQ/QP aggregates. 
Sup35, when not overproduced, forms numerous small aggregates, and partly 
colocalizes with polyQ/QP aggregates. Sup45 was observed to colocalize with polyQ/QP 
in a similar fashion. AQT did not affect the partial colocalization of Sup35 and polyQ/QP, 
or Sup45 and polyQ/QP, respectively. 
The single aggregate per cell formed by overexpressed Sup35 colocalized with 
aggresome formed by 103QP.  
Both presence of [PSI+] and 103Q are able to promote Sup45 aggregation/ 
sequestration. Sup45 is released to the supernatant fraction in AQT strain with either 
103Q or 103QP 
CHAPTER 6 
EFFECT OF CHROMOSOME II EXTRA COPY ON 
[PSI+]-INDEPENDENT POLYGLUTAMINE TOXICITY 
 
Materials 
Strains and Plasmids 
Strains used in the studies discussed in this chapter are in [PIN+ psi-] prion 
background. The WT (GT386) and AQT (GT676) are the [PIN+ psi-] strains cured by 
overexpressing Hsp104 in the respective [PIN+ PSI+] strains GT349 (WT) and GT574 
(AQT No. 7). [PIN+ psi-] strains with deletions on the extra chromosome II in AQT strain 
were obtained initially from the serial deletion analysis in [PIN+ PSI+], and [PSI+] was 
cured by overexpressing Hsp104. 
The Hsp104 plasmid construct used to cure [PSI+] was pLH105 (#198), in which 
HSP104 was fused to the GPD promoter (TDH3 promoter). 
Methods 
Various techniques were used to detect the AQT effect on polyglutamine toxicity 
in [PIN+ psi-] background. These techniques included serial dilution spotting of cultures 
growing in -Ura/Gal (103Q induction culture) at various time points, and additional 
passages from -Ura/Gal onto -Ura/Gal to enlarge the growth difference between strains. 
[PSI+] curing using GPD-HSP104 plasmid was done by passing on YPD for two 
passages, and colony purification to lose the plasmid. Loss of [PSI+] was then confirmed 
by lack of growth on -Ade agar plates. 
Results 
Effect of AQT on Polyglutamine Toxicity in [PIN+] Strains 
While original AQT isolates were all obtained in [PIN+ PSI+] background and 
confirmed to retain both prions, we were interested to know if AQT would cause a similar 
effect in the absence of [PSI+] as well. [psi-] AQT strain together with the isogenic WT 
strain was grown to late logarithmic phase in -Ura/Glu medium. Cells were counted using 
the hemacytometer after 3 times of wash. The induction culture was started with cell 
concentration of 106 cells/ml. Culture was taken from the inoculum and at 24 hr from the 
induction medium and spotted onto -Ura for viability test. AQT was clearly seen to 
decrease 103Q toxicity after 24 hours as compared to the WT (Figure 6.1A). 
We also checked if presence of [PSI+] in AQT and its derivatives affected the 
ability of invading agar plates. Similar to the phenotype observed in [PSI+] (Figure 4.5B), 
loss of agar invasion was seen in both AQT and AQT sup45Δ strains as opposed to the 
isogenic WT (Figure 6.1B). Hence either [PSI+] nor SUP45 was responsible for the lack 
of the capability of agar invasion. 
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Figure 6.1 Effect of AQT in [PIN+ psi-] background.
A – AQT strain ameliorates 103Q toxicity in the [PIN+ psi-] background. Cultures 
were grown in liquid -Ura glucose medium for 1 day, and washed 3 times prior to the 
induction of 103Q in -Ura galactose/raffinose medium. The induction started with the 
cell concentration of 106 cells/ml. Cultures were taken for dilution spotting from the 
inoculum and after induction of 24 h.
B – AQT eliminates the agar invading ability in [PIN+ psi-] background. Deletion of 
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AQT sup45Δ [psi-] strain was tested in polyQ toxicity assay to determine whether 
or not SUP45 was the reason for AQT effect in [psi-] background. Unfortunately, deletion 
of sup45 did not exhibit increase of toxicity even after three passages on -Ura/Gal (Figure 
6.2A). Additionally, excess Sup35C and Sup45 were introduced into UBC4+ WT and 
ubc4Δ WT strains, respectively. No amelioration of polyQ toxicity was detected by plate 
toxicity assay (Figure B and C), indicating that polyglutamine toxicity in [psi-] strain is 
not due to the toxicity through translation termination, an additional mechanism was 
involved in a [PIN+] dependent manner, and a gene other than SUP45 on chromosome II 
was responsible for the AQT effect. 
Mapping the Chromosome II Region Responsible for [PIN+]-Dependent 
Polyglutamine Toxicity 
Utilizing the previously generated chromosome II disomic strains with various 
regional deletions, I created the complete [psi-] set of deletion strains by overexpressing 
Hsp104. Preliminary deletion mapping data confined amelioration of [PIN+]-dependent 
component of poly-Q toxicity to the region 3 of chromosome II (Figure 6.3A). Additional 
deletions within region 3 were depicted in Figure 6.3A. Toxicity assay performed with 
sub-regional deletions made in region 3 confined the location of responsible gene to 
Rg3.2 excluding Rg3.1 (Figure 6.3B). This region corresponds to the nucleotide positions 
102568 to 148377, containing 29 ORFs. This potential region was further divided into 
A
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Figure 6.2 SUP45 is NOT the gene responsible for AQT effects in [PIN+ psi-] 
background.
A – Deletion of sup45 does not eliminate the anti-polyglutamine toxicity in [PIN+ psi-] 
background. Plate is scanned after 3 days of the third passage on –Ura/Gal.
B and C – Introduction of plasmid-borne Sup35C (B) and Sup45 (C) does not 














Figure 6.3 Mapping for [PIN+] dependent polyglutamine toxicity.
A and B– Chromosomal deletions made in region 3 of the extra chromosome II (A). 
Serial deletions made for identifying the gene responsible for AQT in [PIN+ PSI+] 
background are cured of [PSI+] by Hsp104 overexpression. Toxicity assay has 
suggested that Rg3 contains the AQT gene(s) in [psi-] background (B). There are two 
shorter deletions made in Rg3, Rg3.1 and Rg3.2. Polyglutamine is toxic to Rg3.2 
rather than Rg3.1, indicating the middle region of Rg3 (yellow box) contains the 
[PIN+ ]-dependent AQT gene. This middle region is further divided into Rg3.2L1 and 
Rg3.2L2, of which the analysis is yet to be finished.
Rg3.2L1 and Rg3.2L2. Identification of ORF responsible for this effect is currently 
underway. 
Discussion 
The data demonstrate that different yeast prions promote polyglutamine toxicity 
by different mechanisms, namely sequestration of the cytoskeletal components, resulting 
in the effect of endocytosis, in case of Rnq1 prion [PIN+] (Meriin et al. 2003; Meriin et al. 
2007), and sequestration of the release factors in case of Sup35 prion, [PSI+] (this work). 
Additive action of both prions on 103Q toxicity in the absence of P-rich region suggests 
that effects of [PIN+] and [PSI+] are at least partly independent of each other. 
Chromosome II disomy ameliorates both [PSI+]-dependent (via extra-dosage of SUP45) 
and [PIN+]-dependent (via SUP45-unrelated pathway) components of polyQ toxicity. 
However, some level of interference between two sequestration pathways cannot be 
excluded, taking into account the strong anti-toxic effect of the individual overproduction 
of Sup45 or Sup35C in the strain bearing both [PIN+] and [PSI+] prions. 
CHAPTER 7 
EFFECT OF ARGININE BIOSYNTHETIC PATHWAY ON 
POLYGLUTAMINES AND [PSI+] PRION 
 
Materials and Methods 
Strains and Plasmids 
Segregant GT532-9A is the Aqt+  spore obtained from dissection of the diploid 
heterozygous by AQT (No. 2 isolate), which served as the AQT haploid [PSI+] strain. 
Deletions of arg genes were all made in GT532-9A. 
The centromeric plasmid bearing a WT ARG4 gene under its endogenous 
promoter was constructed by inserting PCR amplified fragment Chr VIII 139675-141920 
from genomic DNA, which contains 518 bp upstream and 336 bp downstream of ARG4 
gene, into vector pRS315.  
Methods 
Pulse filed gel electrophoresis was done using the same protocol and parameter 
settings as described in Chapter 3. However, instead of using P32-labelled probes, 
Southern blotting detecting chromosome VIII was done using the Amersham Random 




Effect of Loss of One Copy of Chromosome VIII in the Diploid AQT Strain 
One Aqt- derivative of the diploid homozygous by ubc4Δ and heterozygous by 
AQT1/aqt1-wt was obtained from the transposon mutagenesis screening (Figure 7.1A). 
Interestingly, dissection of this Aqt- diploid derivative on YPD gave a ratio of 2:2 by 
spore viability (Figure 7.1B), indicating a chromosome loss happened to this derivative. 
Loss of that specific chromosome therefore resulted in the loss of AQT phenotype. In 
order to test which chromosome had lost, we performed pulse-field gel electrophoresis 
experiment to separate yeast chromosomes on agarose gel (Figure 7.1C left). Probing 
with chromosome VIII specific probes indicated monosomy of chromosome VIII in the 
Aqt- derivative of Aqt+ diploid (Figure 7.1C right). Next, we checked whether or not 
chromosome VIII contained a gene that was able to affect polyglutamine toxicity. As 
mentioned in Chapter 3, a few centromere linked genes were disrupted to locate the AQT 
gene due to the centromere linkage of AQT indicated by tetrad analysis. ARG4 gene, 
which is close to the centromere of chromosome VIII, was also deleted to determine the 
linkage between AQT and CEN8. Tetrad analysis demonstrated that genes AQT and 
















Figure 7.1 Chromosome VIII monosomic potential from transposon mutagenesis 
library screening.
A – Aqt- derivative shows decreased AQT effect after transposon mutagenesis library 
screening. The Aqt- derivative is one of the potentials obtained from the initial 
screening discussed in Chapter 3.
B – Indication of monosomy in tetrad analysis. Dissection of the Aqt- derivative shows 
viability ratio of 2:2.
C – Confirmation of chromosome VIII monosomy by PFGE and Southern blotting. 
Both original AQT diploid and the Aqt- derivative are tested in duplicates (two 
independent colonies). Chromosome VIII on the CHEF gel is indicated by an arrow. 
ARG4 gene is amplified and used as the template to produce Chr VIII specific probes. 
The chromosome VIII band intensity in Southern blot supports the presence of 























29x(2Arg-Aqt-  : 2Arg+Aqt+) 
14x(2Arg-Aqt-  : 2Arg+Aqt-) 
5x(2Arg-Aqt-  : 1Arg+Aqt+  :1Arg+ Aqt-) 
100 
Note: Toxic effect of arg4Δ on 103Q is discussed in the following section. 
 
Effects of Arg4 Deletion on Polyglutamine Toxicity 
When the haploid arg4Δ AQT was crossed with ARG4 aqt-wt, the dissection was 
expected to yield all three types of tetrads (parental ditype, non parental ditype and 
tetratype), and 2:2 segregation pattern of both Arg+ and Aqt+ (Figure 7.2A). However, all 
Arg- spores were Aqt-. Taking together with the appearance of all 4 Aqt- (PD) and 3 Aqt- 
(T) spores in a tetrad (Figure 7.2B), arg4Δ was able to mask the effect of AQT. 
Surprisingly, deletion of arg4 gene further increased polyQ toxicity in the ubc4Δ aqt1-wt 
haploid strain (Figure 7.2C). Additionally, increase of toxicity was also observed in 
UBC4 aqt1-wt strain, indicating effect of increased toxicity by arg4Δ was independent on 
deletion of UBC4 (Figure 7.2D).  
Figure 7.2 Deletion of ARG4 gene inhibits the effects of AQT.
A – Illustration of tetrad dissection of diploid arg4Δ AQT X ARG4 aqt-wt. All three 
tetrad types are expected if ARG4 and AQT are not linked.
B – Phenotypes of different types of tetrads in tetrad analysis. 
C – Deletion of ARG4 gene in both WT and AQT strains increased polyglutamine 
toxicity.
















arg4Δ aqt-wt UBC4 [103Q]
arg4Δ aqt-wt UBC4 [25Q]
ARG4 aqt-wt UBC4 [103Q]
ARG4 aqt-wt UBC4 [25Q]
D
To test whether or not the increased toxicity was simply due to arg4Δ rather than 
modified regulation of genes next to ARG4, I constructed ARG4 gene with 500bp 
upstream and 300bp downstream flanking regions into yeast centromeric vector pRS315. 
Introduction of a wild type copy of ARG4 into the arg4Δ aqt-wt and arg4Δ AQT haploid 
strains restored the level of toxicity effect as seen in controls (Figure 7.3 A and B).  
Effects of Arg4 Deletion on [PSI+] Phenotypic Expression 
The ade1-14 allele was used to indicate the presence of absence of [PSI+] prion 
due to the cellular function of Sup35 as the translation termination factor. When most of 
Sup35 is in the [PSI+] prion form, recognition of the premature stop codon in ade1-14 
allele is significantly affected, and the readthrough results in the translation of Ade1 
protein and the growth on -Ade medium. When Sup35 is in soluble form in [psi-] strain, 
no complete Ade1 protein is made, therefore there’s no growth on -Ade medium. 
Deletion of arg4 gene did not only increased the polyglutamine toxicity in an AQT 
-independent manner, but also inhibited the [PSI+] phenotypic expression on -Ade 
medium (Figure 7.4A). The lack of growth on -Ade of arg4Δ strain was not due to the 
curing of [PSI+]. The presence of [PSI+] prion was detected by crossing arg4Δ strain 
with WT [psi-] strain (Figure 7.4B). The resulting diploid was able to grow on -Ade 
medium, indicating the arg4Δ strain was indeed [PSI+]. ARG4 gene codes for 
A
arg4Δ AQT ubc4Δ [103Q]
arg4Δ AQT ubc4Δ [103Q][ARG4]
ARG4 AQT ubc4Δ [103Q]
ARG4 aqt-wt ubc4Δ [25Q]
B
Figure 7.3 Complementation assay by introducing plasmid-borne ARG4.
A – Introduction of plasmid CEN-ARG4 in arg4Δ aqt-wt strain eliminates the 
increased polyglutamine toxicity.
B – Introduction of plasmid CEN-ARG4 in arg4Δ AQT strain eliminates the increased 
polyglutamine toxicity.
ARG4 aqt-wt ubc4Δ [103Q]
arg4Δ aqt-wt ubc4Δ [103Q]
arg4Δ aqt-wt ubc4Δ [103Q] [ARG4]










Figure 7.4 Deletion of ARG4 inhibits the manifestation of [PSI+].
A – Loss of phenotypic expression of [PSI+] in arg4Δ strain.
B – Genetic crossing revealed the presence of [PSI+]. Arg4Δ haploid is crossed to [psi-] 
ARG4 strain of the opposite mating type. Resulting diploid is able to grow on –Ade 
plate.
C– Arginine biosynthesis pathway. ARG4 gene codes for argininosuccinate lyase, 

























argininosuccinate lyase, which is responsible for catalyzing the last reaction in the 
arginine biosynthesis pathway (Figure 7.4C).  
Effects of Other Arg Deletions on Polyglutamine Toxicity and [PSI+] Phenotypic 
Expression 
Arginine biosynthesis pathway has been well studied (Henry et al. 1984). Gene 
for argininosuccinate lyase is conserved in a variety of species including Escherichia coli, 
Saccharomyces, algae, rat and human (Yu and Howell 2000). We further deleted genes 
ARG1 and ARG8 along this pathway. Deletion of arg1 behaved very similarly to arg4Δ 
in polyQ toxicity assay whereas arg8Δ didn’t have much additive effect (Figure 7.5A). 
All three arg deletions were able to block the manifestation of [PSI+] on -Ade medium 
(Figure 7.5B). With extra Arginine in the medium, growth of arg deletions was increased 
but still much worse than controls (Figure 7.5C). 
Accumulation of red pigment in cells is another phenotypic expression of lack of 
[PSI+]. We tested all three arg deletions with WT on YPD. Only arg4 exhibited slightly 
darker red color (Figure 7.5D). 
 Deletions of arg genes were crossed with UBC4+ WT strain to generate UBC4 
arg1Δ, UBC4 arg4Δ, and UBC4 arg8Δ, respectively. UBC4 arg8Δ were able to grow as 
opposed to UBC4 arg1Δ and UBC4 arg4Δ strains (Figure 7.5E). 
Are Effects of Arginine Biosynthetic Pathway Related to Polyamine Biosynthesis? 
Figure 7.5 Effects of Arg deletions on polyglutamine toxicity and [PSI+].
A – Polyglutamine toxicity assay of Arg deletions. arg1Δ and arg4Δ increases 
polyglutamine toxicity, whereas arg8Δ does not have the effect as the other two 
deletions
B– All three arg deletions inhibit manifestation of [PSI+]
C – Extra arginine partially restores phenotypic expression of [PSI+]. 4X arginine was 
added into the –Ade medium.
D – Color assay of arg deletions. Arg4Δ shows a darker red color when compared to 
other arg deletions as well as the WT control.
E – In the presence of UBC4 WT, arg8Δ exhibits partial suppression of [PSI+] 
phenotypic expression.
-Ura/Gal -Ade -Ade 
4X Arginine
aqt-wt arg1Δ ARG4 ARG8 [103Q]
aqt-wt ARG1 arg4Δ ARG8 [103Q]
aqt-wt ARG1 ARG4 arg8Δ [103Q]
aqt-wt ARG1 ARG4 ARG8 [103Q]
AQT ARG1 ARG4 ARG8 [103Q]













Ornithine decarboxylase relates Arginine biosynthesis intermediate, ornithine, to 
polyamine biosynthesis (Tabor and Tabor 1984). Expanded polyglutamine proteins 
promoted spermine synthesis and led to increase of polyglutamine aggregation and cell 
death. Moreover, cell death was inhibited when there was an ornithine decarboxylase 
antagonist (Colton et al. 2004). We then hypothesized that in the yeast model deficiency 
of Arg1p and Arg4p resulted in the accumulation of ornithine, thus stimulating 
polyamine biosynthesis (Figure 7.6A). We started testing this hypothesis by deleting 
SPE1 gene, coding for ornithine decarboxylase. Deletion of spe1 did not affect 
polyglutamine toxicity (Figure 7.6B). However, [PSI+] phenotypic expression was 
suppressed by spe1Δ (Figure 7.6C). 
Discussions 
We have shown that monosomy of chromosome VIII increases polyglutamine 
toxicity in diploid heterozygous by AQT. Deletion of ARG4 that is located on 
chromosome VIII increases polyQ toxicity by the mechanism unrelated to AQT or ubc4Δ. 
The increase of polyglutamine toxicity is exclusively due to loss of the Arg4 protein in 
the arg4Δ strain rather than deletion induced modification of ARG4 neighbor genes. 
These findings indicate that effect of ARG4 on polyglutamine toxicity is 
dosage-dependent. 
A
Figure 7.6 Relation between Arginine biosynthesis and polyamine biosynthesis.
A – Schematic view of argine and polyamine biosynthesis pathways. Ornithine 
connects argine and polyamine synthesis in yeast. The hypothesis is that the increase 
of level of polyamine due to the imbalance created by loss of Arg1 or Arg4 may result 
in the increase in polyglutamine toxicity, and eventually cell death.
B and C – Effect of spe1Δ on polyglutamine toxicity and [PSI+] manifestation. No 
obvious effect of deletion of spe1 is observed in polyQ toxicity assay. However, spe1Δ

























Deletion of arg8 involved in steps before ornithine synthesis as well as deletion of 
spe1 did not increase polyglutamine toxicity. Whereas, deletion of genes arg1 and arg4 
controlling steps after ornithine caused even severe polyglutamine toxicity. These data 
indicated that ornithine was likely involved in the increased polyQ toxicity, however not 
through polyamine biosynthesis. On the other hand, deletions of genes involved in 
Arginine and Polyamine biosynthesis were all able to affect [PSI+] phenotypic expression, 
indicating factors utilizing Arginine and/or Spermine might be responsible.  
GENERAL CONCLUSIONS 
 PolyQ or polyQP are toxic in the presence of [PSI+], a prion form of 
translation termination factor Sup35. 
 Effects of Anti-polyQ-toxicity (AQT) strains result from disomy by 
chromosome II. 
 The extra copy of SUP45 gene on duplicated chromosome II is responsible 
for AQT in [PSI+] background. 
 Increased level of Sup45p is more strictly controlled in the presence of WT 
Ubc4. 
 Excess of the termination factor Sup45 or non-prion derivative of the 
termination factor  Sup35 (Sup35C) ameliorates polyQ/QP toxicity. 
 Function of Sup45 is required for AQT effect. 
 Sup35/Sup35NM aggregates colocalize with polyglutamine aggregates. 
 Size range of Sup35 polymers is broadened in the presence of 103Q or 
103QP, and AQT strain is able to reduce the size of Sup35 polymers. 
 Sup45 is sequestered to aggregates in the presence of polyglutamine or [PSI+] 
prion. 
 Phenotypes, such as lack of agar invasion and temperature resistance, are not 
associated with excess Sup45. 
 Chromosome II disomy is responsible for AQT effect in [PIN+ psi-] 
background. However, the mechanism is independent on SUP45. 
 Gene(s) within chromosome II nucleotide positions 102568 and 148377 is 
responsible for AQT in [PIN+ psi-]. 
 Chromosome VIII disomy and deletions of arg4 and arg1 cause 
polyglutamine toxicity independent on Sup45. 
 Phenotypic expression of [PSI+] is suppressed by deletions of arg1, arg4, 
arg8, and spe1. 
APPENDIX A 
LIST OF STRAINS IN NUMERICAL ORDER 
 
 Yeast strains used in this study were listed in the table below. 
 
Table A.1 List of strains in numerical order 
Strain Genotype 
GT81-1C MAT a  ade1-14  his3-Δ200 or 11,15  leu2-3,112  lys2  trp1-Δ  ura3-52  
[PSI+ PIN+] 
GT349 MAT a  ade1-14  Δubc4::HIS3 his3-Δ200 or 11.15  leu2-3,112  lys2  
trp1-Δ  ura3-52  [PSI+ PIN+] 
GT409 MAT a  ade1-14  his3-Δ200 or 11,15  leu2-3,112  lys2  trp1-Δ  ura3-52 
[psi- pin-] 
GT532-9A MAT a  ade1-14  Δubc4::HIS3 his3-Δ200(or -11, 15) leu2-3,112  lys2  
trp1-Δ  [#607 URA] ura3-52  [PSI+ PIN+] 
GT532 ade1-14/ade1-14  Δubc4::HIS3/ubc4::HIS3 his3-Δ200(or -11, 15)/ his3-
Δ200(or -11, 15) leu2-3,112/leu2-3,112  lys2/lys2  trp1-Δ/trp1-Δ  ura3-
52/ura3-52 [pYES2-103Q] [PSI+ PIN+] 
GT534 ade1-14/ade1-14  Δubc4::HIS3/ubc4::HIS3 his3-Δ200(or -11, 15)/ his3-
Δ200(or -11, 15) leu2-3,112/leu2-3,112  lys2/lys2  trp1-Δ/trp1-Δ  ura3-
52/ura3-52 [pYES2-103Q] [PSI+ PIN+] 
GT573 MAT a  ade1-14  Δubc4::HIS3 his3-Δ200 or 11.15  leu2-3,112  lys2  
trp1-Δ  ura3-52  [PSI+ PIN+] (antitoxic papilla 2a’) 
GT574 MAT a  ade1-14  Δubc4::HIS3 his3-Δ200 or 11.15  leu2-3,112  lys2  
trp1-Δ  ura3-52  [PSI+ PIN+] (antitoxic papilla 7a’) 
GT575 MAT a  ade1-14  Δubc4::HIS3 his3-Δ200 or 11.15  leu2-3,112  lys2  
trp1-Δ  ura3-52  [PSI+ PIN+] (antitoxic papilla 9a’) 
GT1161 MAT a Δarg4::KanMX6 ade1-14  Δubc4::HIS3 his3-Δ200(or -11, 15) 
leu2-3,112  lys2  trp1-Δ  ura3-52  [PSI+ PIN+] 
GT1162 a/α Δarg4::KanMX6/ARG4 ade1-14/ ade1-14 Δubc4::HIS3/UBC4 his3-
Δ200 or 11,15/ his3-Δ200 or 11,15  leu2-3,112/ leu2-3,112  lys2/ lys2  
trp1-Δ/ trp1-Δ  ura3-52/ ura3-52  [PSI+ PIN+] 
GT1163 MAT a Δarg4::KanMX6 ade1-14  Δubc4::HIS3 his3-Δ200(or -11, 15) 
leu2-3,112  lys2  trp1-Δ  ura3-52 [pYES2-103Q] [PSI+ PIN+] 
GT1164 MAT a Δarg4::KanMX6 ade1-14  Δubc4::HIS3 his3-Δ200(or -11, 15) 
leu2-3,112  lys2  trp1-Δ  ura3-52 [pYES2-103Q] [PSI+ PIN+] 
GT1202 MAT a Δmet28::KanMX6 ade1-14  Δubc4::HIS3 his3-Δ200(or -11, 15) 
leu2-3,112  lys2  trp1-Δ  ura3-52  [PSI+ PIN+] 
GT1203 MAT a Δmet3::KanMX6 ade1-14  Δubc4::HIS3 his3-Δ200(or -11, 15) 
leu2-3,112  lys2  trp1-Δ  ura3-52  [PSI+ PIN+] 
GT1204 MAT a Δmet14::KanMX6 ade1-14  Δubc4::HIS3 his3-Δ200(or -11, 15) 
leu2-3,112  lys2  trp1-Δ  ura3-52  [PSI+ PIN+] 
GT1205 a/α Δmet28::KanMX6/MET28 aqt1-wt/AQT1-2 ade1-14/ ade1-14 
Δubc4::HIS3/Δubc4::HIS3 his3-Δ200 or 11,15/ his3-Δ200 or 11,15  
leu2-3,112/ leu2-3,112  lys2/ lys2  trp1-Δ/ trp1-Δ  ura3-52/ ura3-52  
[PSI+ PIN+] 
GT1206 a/α Δmet3::KanMX6/MET3 aqt1-wt/AQT1-2 ade1-14/ ade1-14 
Δubc4::HIS3/Δubc4::HIS3 his3-Δ200 or 11,15/ his3-Δ200 or 11,15  
leu2-3,112/ leu2-3,112  lys2/ lys2  trp1-Δ/ trp1-Δ  ura3-52/ ura3-52  
[PSI+ PIN+] 
GT1207 a/α Δmet14::KanMX6/MET14 aqt1-wt/AQT1-2 ade1-14/ ade1-14 
Δubc4::HIS3/Δubc4::HIS3 his3-Δ200 or 11,15/ his3-Δ200 or 11,15  
leu2-3,112/ leu2-3,112  lys2/ lys2  trp1-Δ/ trp1-Δ  ura3-52/ ura3-52  
[PSI+ PIN+] 
GT1219 MAT a ade1-14  Δubc4::KanMX6 his3-Δ200(or -11, 15) leu2-3,112  lys2  
trp1-Δ  ura3-52  [PSI+ PIN+] 
GT1221 MAT a  ade1-14 Δubc4::HIS3 his3-Δ200(or -11, 15) leu2-3,112  lys2  
ura3-52  [PSI+ PIN+] 
GT1223 MAT a Δarg1::KanMX6 ade1-14  Δubc4::HIS3 his3-Δ200(or -11, 15) 
leu2-3,112  lys2  trp1-Δ  ura3-52  [PSI+ PIN+] 
GT1224 MAT a Δarg8::KanMX6 ade1-14  Δubc4::HIS3 his3-Δ200(or -11, 15) 
leu2-3,112  lys2  trp1-Δ  ura3-52  [PSI+ PIN+] 
Table A.1 List of strains in numerical order (continuation)
GT1277 a/α Δarg1::KanMX6/ARG1 aqt1-wt/aqt1-wt ade1-14/ ade1-14 
Δubc4::HIS3/UBC4 his3-Δ200 or 11,15/ his3-Δ200 or 11,15  leu2-3,112/ 
leu2-3,112  lys2/ lys2  trp1-Δ/ trp1-Δ  ura3-52/ ura3-52  [#874]  [PSI+ 
PIN+] 
GT1278 a/α Δarg8::KanMX6/ARG8 aqt1-wt/aqt1-wt ade1-14/ ade1-14 
Δubc4::HIS3/UBC4 his3-Δ200 or 11,15/ his3-Δ200 or 11,15  leu2-3,112/ 
leu2-3,112  lys2/ lys2  trp1-Δ/ trp1-Δ  ura3-52/ ura3-52  [#874]  [PSI+ 
PIN+] 
GT1279 a/α Δarg1::KanMX6/ARG1 aqt1-wt/aqt1-wt ade1-14/ ade1-14 
Δubc4::HIS3/Δubc4::HIS3 his3-Δ200 or 11,15/ his3-Δ200 or 11,15  
leu2-3,112/ leu2-3,112  lys2/ lys2  trp1-Δ/ trp1-Δ  ura3-52/ ura3-52  
[#874] [PSI+ PIN+] 
GT1280 a/α Δarg8::KanMX6/ARG8 aqt1-wt/aqt1-wt ade1-14/ ade1-14 
Δubc4::HIS3/Δubc4::HIS3 his3-Δ200 or 11,15/ his3-Δ200 or 11,15  
leu2-3,112/ leu2-3,112  lys2/ lys2  trp1-Δ/ trp1-Δ  ura3-52/ ura3-52  
[#874] [PSI+ PIN+] 
GT1281 MAT α ade1-14  Δubc4::KanMX6/Δubc4::HIS3 AQT1-2 his3-Δ200(or -
11, 15) leu2-3,112  lys2  trp1-Δ  ura3-52  [#874] [PSI+ PIN+] 
GT1282 MAT a ade1-14  Δubc4::KanMX6/Δubc4::HIS3 AQT1-2 his3-Δ200(or -
11, 15) leu2-3,112  lys2  trp1-Δ  ura3-52  [#874] [PSI+ PIN+] 
GT1283 MAT α ade1-14  Δspe1::KanMX6 Δubc4::HIS3 aqt1-wt his3-Δ200(or -
11, 15) leu2-3,112  lys2  trp1-Δ  ura3-52  [#874] [PSI+ PIN+] 
GT1299 a/α Δspe1::KanMX6/SPE1 aqt1-wt/aqt1-wt ade1-14/ ade1-14 
Δubc4::HIS3/UBC4 his3-Δ200 or 11,15/ his3-Δ200 or 11,15  leu2-3,112/ 
leu2-3,112  lys2/ lys2  trp1-Δ/ trp1-Δ  ura3-52/ ura3-52  [#874] [PSI+ 
PIN+] 
GT1305 a/α Δspe1::KanMX6/SPE1 AQT1-2/aqt1-wt ade1-14/ ade1-14 
Δubc4::HIS3/Δubc4::HIS3 his3-Δ200 or 11,15/ his3-Δ200 or 11,15  
leu2-3,112/ leu2-3,112  lys2/ lys2  trp1-Δ/ trp1-Δ  ura3-52/ ura3-52  
[PSI+ PIN+] 
GT1343 MAT a  ade1-14 Δpep1::pGSHU cassette  Δubc4::HIS3 his3-Δ200 or 
11.15  leu2-3,112  lys2  trp1-Δ  ura3-52  [PSI+ PIN+] 
GT1344 MAT a  ade1-14 Δpep1::pGSHU cassette  Δubc4::HIS3 his3-Δ200 or 
11.15  leu2-3,112  lys2  trp1-Δ  ura3-52  [PSI+ PIN+]  
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GT1349 MAT a  ade1-14 Δira1::pGSHU cassette  Δubc4::HIS3 his3-Δ200 or 
11.15  leu2-3,112  lys2  trp1-Δ  ura3-52  [PSI+ PIN+] 
GT1350 MAT a  ade1-14 Δira1::pGSHU cassette  Δubc4::HIS3 his3-Δ200 or 
11.15  leu2-3,112  lys2  trp1-Δ  ura3-52  [PSI+ PIN+] 
GT1443 a/α  ade1-14/ade1-14  Δubc4::HIS3/ubc4::HIS3 his3-Δ200(or -11, 15)/ 
his3-Δ200(or -11, 15) leu2-3,112/leu2-3,112  lys2/lys2  trp1-Δ/trp1-Δ  
ura3-52/ura3-52 [PSI+ PIN+] 
GT1452 a/α  ade1-14/ade1-14  Δubc4::HIS3/ubc4::HIS3 his3-Δ200(or -11, 15)/ 
his3-Δ200(or -11, 15) leu2-3,112/leu2-3,112  lys2/lys2  trp1-Δ/trp1-Δ  
ura3-52/ura3-52, PEP1/Δpep1::pGSHU cassette  [PSI+ PIN+] 
GT1465 MAT a  ade1-14 Δola1-Δira1::LEU2  Δubc4::HIS3 his3-Δ200 or 11.15  
leu2-3,112  lys2  trp1-Δ  ura3-52  [PSI+ PIN+] 
GT1466 MAT a  ade1-14 Δ ira1-Δsnf5::LEU2  Δubc4::HIS3 his3-Δ200 or 11.15  
leu2-3,112  lys2  trp1-Δ  ura3-52  [PSI+ PIN+] 
GT1467 MAT a  ade1-14 Δ boi1-Δpep1::LEU2  Δubc4::HIS3 his3-Δ200 or 11.15  
leu2-3,112  lys2  trp1-Δ  ura3-52  [PSI+ PIN+] 
GT1471 MAT a  ade1-14 Δ ira1-Δmsi1::LEU2  Δubc4::HIS3 his3-Δ200 or 11.15  
leu2-3,112  lys2  trp1-Δ  ura3-52  [PSI+ PIN+] 
GT1472 MAT a  ade1-14 Δ ira1-Δert1::LEU2  Δubc4::HIS3 his3-Δ200 or 11.15  
leu2-3,112  lys2  trp1-Δ  ura3-52  [PSI+ PIN+] 
GT1473 MAT a  ade1-14 Δ kip1-Δpep1::LEU2  Δubc4::HIS3 his3-Δ200 or 11.15  
leu2-3,112  lys2  trp1-Δ  ura3-52  [PSI+ PIN+] 
GT1474 MAT a  ade1-14 Δ apl3-Δpep1::LEU2  Δubc4::HIS3 his3-Δ200 or 11.15  
leu2-3,112  lys2  trp1-Δ  ura3-52  [PSI+ PIN+] 
GT1490 MAT a  ade1-14 csh1Δ::pGSHU CSH1 Δubc4::HIS3 his3-Δ200 or 11.15  
leu2-3,112  lys2  trp1-Δ  ura3-52  [PSI+ PIN+] 
GT1491 MAT a  ade1-14 YBR184WΔ::pGSHU YBR184W Δubc4::HIS3 his3-
Δ200 or 11.15  leu2-3,112  lys2  trp1-Δ  ura3-52  [PSI+ PIN+] 
GT1492 MAT a  ade1-14 Δ ira1-Δapd1::LEU2  Δubc4::HIS3 his3-Δ200 or 11.15  
leu2-3,112  lys2  trp1-Δ  ura3-52  [PSI+ PIN+] 
GT1493 MAT a  ade1-14 Δ apd1-Δcsh1::LEU2  Δubc4::HIS3 his3-Δ200 or 11.15  
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leu2-3,112  lys2  trp1-Δ  ura3-52  [PSI+ PIN+] 
GT1494 MAT a  ade1-14 Δ csh1-Δnpl4::LEU2  Δubc4::HIS3 his3-Δ200 or 11.15  
leu2-3,112  lys2  trp1-Δ  ura3-52  [PSI+ PIN+] 
GT1495 MAT a  ade1-14 Δ npl4-Δybr184w::LEU2  Δubc4::HIS3 his3-Δ200 or 
11.15  leu2-3,112  lys2  trp1-Δ  ura3-52  [PSI+ PIN+] 
GT1496 MAT a  ade1-14 Δ ybr184w-Δmsi1::LEU2  Δubc4::HIS3 his3-Δ200 or 
11.15  leu2-3,112  lys2  trp1-Δ  ura3-52  [PSI+ PIN+] 
GT1544 MAT a  ade1-14 Δ ira1-Δmak5::LEU2  Δubc4::HIS3 his3-Δ200 or 11.15  
leu2-3,112  lys2  trp1-Δ  ura3-52  [PSI+ PIN+] 
GT1546 MAT a  ade1-14 Δ mak5-Δrtc2::LEU2  Δubc4::HIS3 his3-Δ200 or 11.15  
leu2-3,112  lys2  trp1-Δ  ura3-52  [PSI+ PIN+] 
GT1547 MAT a  ade1-14 Δ rtc2-Δara1::LEU2  Δubc4::HIS3 his3-Δ200 or 11.15  
leu2-3,112  lys2  trp1-Δ  ura3-52  [PSI+ PIN+] 
GT1553 MAT a  ade1-14 Δ sup45-Δadh5::LEU2  Δubc4::HIS3 his3-Δ200 or 
11.15  leu2-3,112  lys2  trp1-Δ  ura3-52  [PSI+ PIN+] 
GT1555 MAT a  ade1-14 Δ SUP45/sup45::LEU2  Δubc4::HIS3 his3-Δ200 or 
11.15  leu2-3,112  lys2  trp1-Δ  ura3-52  [PSI+ PIN+] 
GT1559 MAT a/α  Δubc4::HIS3/ Δubc4::HIS3 ade1-14/ade1-14   leu2-3, 
112/leu2-3, 112   his3-Δ200(or -11, 15)/his3-Δ200(or -11, 15)   lys2/lys2 
trp1-Δ/trp1-Δ   ura3-52/ura3-52  [PSI+ PIN+] 
GT1564 MAT a/α  SUP45/Δsup45::HygR ade1-14/ade1-14   leu2-3, 112/leu2-3, 
112   his3-Δ200(or -11, 15)/his3-Δ200(or -11, 15)   lys2/lys2 trp1-Δ/trp1-
Δ   ura3-52/ura3-52   [PSI+ PIN+] 
GT1564-1C MAT α  Δsup45::HygR ade1-14 leu2-3, 112   his3-Δ200(or -11, 15) lys2 
trp1-Δ ura3-52  [psi- PIN+] [#1160] 
GT1564-3B MATα  Δsup45::HygR ade1-14 leu2-3, 112   his3-Δ200(or -11, 15) lys2 
trp1-Δ ura3-52 [psi- PIN+] [#1162] 
GT1568 MAT a  ade1-14 Δ sup45::LEU2  Δubc4::HIS3 his3-Δ200 or 11.15  leu2-
3,112  lys2  trp1-Δ  ura3-52  [psi- PIN+] 
GT1576 MAT a/α  SUP45/Δsup45::HygR ade1-14/ade1-14   leu2-3, 112/leu2-3, 
112   his3-Δ200(or -11, 15)/his3-Δ200(or -11, 15)   lys2/lys2 trp1-Δ/trp1-
Δ   ura3-52/ura3-52  [#1160 CEN-LEU2-SUP45] [PSI+ PIN+] 
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GT1577 MAT a/α  UBC4/ Δubc4::HIS3 SUP45/Δsup45::HygR ade1-14/ade1-14   
leu2-3, 112/leu2-3, 112   his3-Δ200(or -11, 15)/his3-Δ200(or -11, 15)   
lys2/lys2 trp1-Δ/trp1-Δ   ura3-52/ura3-52  [#1160 CEN-LEU2-SUP45] 
[PSI+ PIN+] 
GT1577-1B MATα   Δubc4::HIS3  Δsup45::HygR  ade1-14   leu2-3, 112 his3-
Δ200(or -11, 15)   lys2 trp1-Δ   ura3-52  [#1160 CEN-LEU2-SUP45] 
[PSI+ PIN+] 
GT1578 MATa/α  UBC4/ Δubc4::HIS3 SUP45/Δsup45::HygR ade1-14/ade1-14   
leu2-3, 112/leu2-3, 112   his3-Δ200(or -11, 15)/his3-Δ200(or -11, 15)   
lys2/lys2 trp1-Δ/trp1-Δ   ura3-52/ura3-52  [#1160 CEN-LEU2-SUP45]
  [psi- PIN+] 
GT1578-1C MATα    Δubc4::HIS3  Δsup45::HygR ade1-14 leu2-3, 112   his3-
Δ200(or -11, 15)   lys2 trp1-Δ   ura3-52  [#1160 CEN-LEU2-SUP45] 
[psi- PIN+] 
GT1579 MATa/α  SUP45/Δsup45::HygR ade1-14/ade1-14   leu2-3, 112/leu2-3, 
112   his3-Δ200(or -11, 15)/his3-Δ200(or -11, 15)   lys2/lys2 trp1-Δ/trp1-
Δ   ura3-52/ura3-52  [#1162 CEN-URA3-SUP45] [PSI+ PIN+] 
GT1580 MATa/α  UBC4/ Δubc4::HIS3 SUP45/Δsup45::HygR ade1-14/ade1-14   
leu2-3, 112/leu2-3, 112   his3-Δ200(or -11, 15)/his3-Δ200(or -11, 15)   
lys2/lys2 trp1-Δ/trp1-Δ   ura3-52/ura3-52  [#1162 CEN-URA3-SUP45]
  [PSI+ PIN+] 
GT1581 MATa/α  UBC4/ Δubc4::HIS3 SUP45/Δsup45::HygR ade1-14/ade1-14   
leu2-3, 112/leu2-3, 112   his3-Δ200(or -11, 15)/his3-Δ200(or -11, 15)   
lys2/lys2 trp1-Δ/trp1-Δ   ura3-52/ura3-52  [#1162 CEN-URA3-SUP45]
  [psi- PIN+] 
GT1603 MATa/α  Δubc4::HIS3/ Δubc4::HIS3 SUP45/Δsup45::HygR ade1-
14/ade1-14   leu2-3, 112/leu2-3, 112   his3-Δ200(or -11, 15)/his3-
Δ200(or -11, 15)   lys2/lys2 trp1-Δ/trp1-Δ   ura3-52/ura3-52 [psi- PIN+] 
GT1604 MAT a  ade1-14 Δola1-Δira1::LEU2  Δubc4::HIS3 his3-Δ200 or 11.15  
leu2-3,112  lys2  trp1-Δ  ura3-52  [psi- PIN+] 
GT1605 MAT a  ade1-14 Δ ira1-Δsnf5::LEU2  Δubc4::HIS3 his3-Δ200 or 11.15  
leu2-3,112  lys2  trp1-Δ  ura3-52  [psi- PIN+] 
GT1606 MAT a  ade1-14 Δ boi1-Δpep1::LEU2  Δubc4::HIS3 his3-Δ200 or 11.15  
leu2-3,112  lys2  trp1-Δ  ura3-52  [psi- PIN+] 
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GT1607 MAT a  ade1-14 Δ  ira1-Δmsi1::LEU2  Δubc4::HIS3 his3-Δ200 or 11.15  
leu2-3,112  lys2  trp1-Δ  ura3-52  [psi- PIN+] 
GT1608 MAT a  ade1-14 Δ ira1-Δert1::LEU2  Δubc4::HIS3 his3-Δ200 or 11.15  
leu2-3,112  lys2  trp1-Δ  ura3-52  [psi- PIN+] 
GT1609 MAT a  ade1-14 Δ kip1-Δpep1::LEU2  Δubc4::HIS3 his3-Δ200 or 11.15  
leu2-3,112  lys2  trp1-Δ  ura3-52  [psi- PIN+] 
GT1610 MAT a  ade1-14 Δ apl3-Δpep1::LEU2  Δubc4::HIS3 his3-Δ200 or 11.15  
leu2-3,112  lys2  trp1-Δ  ura3-52  [psi- PIN+] 
GT1611 MAT a  ade1-14 Δ ira1-Δapd1::LEU2  Δubc4::HIS3 his3-Δ200 or 11.15  
leu2-3,112  lys2  trp1-Δ  ura3-52  [psi- PIN+] 
GT1612 MAT a  ade1-14 Δ apd1-Δcsh1::LEU2  Δubc4::HIS3 his3-Δ200 or 11.15  
leu2-3,112  lys2  trp1-Δ  ura3-52  [psi- PIN+] 
GT1613 MAT a  ade1-14 Δ csh1-Δnpl4::LEU2  Δubc4::HIS3 his3-Δ200 or 11.15  
leu2-3,112  lys2  trp1-Δ  ura3-52  [psi- PIN+] 
GT1614 MAT a  ade1-14 Δ npl4-Δybr184w::LEU2  Δubc4::HIS3 his3-Δ200 or 
11.15  leu2-3,112  lys2  trp1-Δ  ura3-52  [psi- PIN+] 
GT1615 MAT a  ade1-14 Δ ybr184w-Δmsi1::LEU2  Δubc4::HIS3 his3-Δ200 or 
11.15  leu2-3,112  lys2  trp1-Δ  ura3-52  [psi- PIN+] 
GT1616 MAT a  ade1-14 Δ ira1-Δmak5::LEU2  Δubc4::HIS3 his3-Δ200 or 11.15  
leu2-3,112  lys2  trp1-Δ  ura3-52  [psi- PIN+] 
GT1617 MAT a  ade1-14 Δ mak5-Δrtc2::LEU2  Δubc4::HIS3 his3-Δ200 or 11.15  
leu2-3,112  lys2  trp1-Δ  ura3-52  [psi- PIN+] 
GT1618 MAT a  ade1-14 Δ rtc2-Δara1::LEU2  Δubc4::HIS3 his3-Δ200 or 11.15  
leu2-3,112  lys2  trp1-Δ  ura3-52  [psi- PIN+] 
GT1619 MAT a  ade1-14 Δ sup45-Δadh5::LEU2  Δubc4::HIS3 his3-Δ200 or 
11.15  leu2-3,112  lys2  trp1-Δ  ura3-52  [psi- PIN+] 
GT1620 MATa/α  Δubc4::HIS3/ Δubc4::HIS3 SUP45/Δsup45::HygR ade1-
14/ade1-14   leu2-3, 112/leu2-3, 112   his3-Δ200(or -11, 15)/his3-
Δ200(or -11, 15)   lys2/lys2 trp1-Δ/trp1-Δ   ura3-52/ura3-52  
[#1160 CEN-LEU2-SUP45] [PSI+ PIN+] 
GT1665 a/α ade1-14/ade1-14   leu2-3, 112/leu2-3, 112   his3-Δ200(or -11, 
15)/his3-Δ200(or -11, 15)   lys2/lys2 trp1-Δ/trp1-Δ   ura3-52/ura3-52 
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ubc4Δ/ubc4Δ/UBC4 trisomic ChrII   [#874] [PSI+ PIN+] 
OT147 MATα his5 
OT148 MATa his5 
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APPENDIX B 
LIST OF PLASMIDS IN NUMERICAL ORDER 
 
 Plasmids used in this study were listed in the table below. 
Table B.1 List of plasmids in numerical order 
No. Protein Plasmid Marker/Type 
Promot
er Reference 
3 N/A pRS316-GAL URA3/CEN GAL1 
(Liu et al. 
1992) 












191 Sup45DelC5 YEp13-SUP1 LEU2/2μ SUP35 
(Chernoff et 
al. 1992) 
210 Sup35C pRS315-SUP35 del3ATG 
LEU2/CE









se w/ UGA 
stop codon 
pUKC819 URA3/2μ PGK (Firoozan et al. 1991) 
303 Sup45 pGAL-SUP45 Library URA3/CEN 
GAL1-
10 G. Newnam 
564 Ubc4 pTRP-UBC4 TRP1/2μ GAL1 Dr. Braun 
659 Htt-25Q pYES-Q25trp TRP1/2μ GAL1 (Wang et al. 2009) 
660 Htt-103Q pYES-Q103trp TRP1/2μ GAL1 (Wang et al. 2009) 
872 Htt-25Q pYES2-25Q URA3/2μ GAL1 (Meriin et al. 2002) 
873 Htt-25QP pYES2-25QP URA3/2μ GAL1 (Meriin et al. 2007) 
874 Htt-103Q pYES2-103Q URA3/2μ GAL1 (Meriin et al. 2002) 
875 Htt-103QP pYES2-103QP URA3/2μ GAL1 (Meriin et al. 2007) 
1058 Arg4 pRS315_ARG4 LEU2/CEN ARG4 This study 
1059 Arg4 CEN-AL LEU2/CEN ARG4 This study 
1068 N/A pFL35 TRP1/2μ N/A (Bonneaud et al. 1991) 
1086 N/A pGSHU Hyg
R 




1087 Ump1 pRS316-GAL-UMP1 URA3/CEN GAL1 This study 
1090 Ump1 pRS315-UMP1 LEU2/CEN UMP1 This study 
1100 Sup35NM pCUP-Sup35NM-DsRed 
LEU2/CE
N CUP This study 
1150 Sup45 pRS315-SUP45-ADH5 LEU2/CEN SUP45 This study 
1151 Sup45 pRS315-GAL-SUP45cDNA 
LEU2/CE
N GAL1 This study 




ra et al. 
2009) 
1160 Sup45 pRS315-SUP45 LEU2/CEN SUP45 
(Le Goff et 
al. 2002) 




o et al. 
2004) 
1162 Sup45 pRS316-SUP45 URA3/CEN SUP45 
(Le Goff et 
al. 2002) 







et al. 2006) 
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APPENDIX C 
LIST OF PRIMERS 
 
 Primers used in this study were synthesized by IDT or Invitrogen and were DNA 
oligonucleotides without specific additional modifications. Dry primers were 
resuspended in the ddH2O to the concentration of 250 μM as the stock. The list of 
primers is in the table below. 
 
Table C.1 List of primers in numerical order 
Number Primer Sequence 
554 10_MET3_F ACTATTACACTTCATTTACCACCCTCTGATCTAGATTTTCCGGATCCCCGGGTTAATTAA 
555 9_MET28_R GTGAGTCAAGGCCGGGCAGCCAATGACTAAGAACACGAGGGAATTCGAGCTCGTTTAAAC 
556 9_MET28_F ACGTTTCGCGGGCTACCTGCCCATGTTCCGTCTCTTAATGCGGATCCCCGGGTTAATTAA 
557 10_MET3_R GTACAATATGTGAAATAGGTTCATCCGCTGACTCTAGCTGGAATTCGAGCTCGTTTAAAC 
558 11_MET14_F TGTACAGTAATCGGTCAAATTACAAATGCTTACGGATGATCGGATCCCCGGGTTAATTAA 
559 11_MET14_R CAAGAAAAGTTGGAATTATTTCTCCAAGCACACTGTACACGAATTCGAGCTCGTTTAAAC 
686 PRSQZ CGACGGGATCCCCCTTAACG 
687  9_MET28_ChF CGACAGTTCCATGTCGCGAG 
688  9_MET28_ChR AAGGGGTACTGAGTGCACGT 
689 10_MET3_ChF AGATGCTCAGAATACCCGTC 
690 10_MET3_ChR GCGGTCGATCATGAATTTTG 
691 11_MET14_ChF TCTATGAGCGAGGCCACTGG 
692 11_MET14_ChR TGCGTATCCGTTAATGTCGT 
693 F_pRS315_ARG4 CTGGGATCCTATTTAGTCTCATGGCCATT 
694 R_pRS315_ARG4 ATCCTCTAGACTGTCAGAGACTGTTCCTT 
695 Chk9_MET28_F TTGATCAATGCGGAGTGGGA 
696 Chk9_MET28_R GTACTGAGTGCACGTGACTT 
697 HIS2_Chk_Fwd GATCCAAAGCCGTTCTAGAT 
698 HIS2_Chk_Rvs ATTTGAGTAGCTCGTCAAGG 
699 HIS2_Del_Rvs CGATCAAGTGGTCAACCTCAACTTTCACACGTACTGTTTGCGGATCCCCGGGTTAATTAA 
700 HIS2_Del_Fwd ATGTTGAACTTCCAGATGCGGCCGAGTCGGCGAGCAAACAGAATTCGAGCTCGTTTAAAC 
701 ARG1_Del_For GCAGTTGCGAGACCCAGACTGGCACTGTCTCAATAGTATAGAATTCGAGCTCGTTTAAAC 
702 ARG1_Del_Rev TACCCTTATACAGTCTAACCCTGACAGTACCGTTAACGCTCGGATCCCCGGGTTAATTAA 
703 ARG8_Del_Rev TTTTTGATGACCTCGGTGGGTGGTTCGACGAACTCAGCACGAATTCGAGCTCGTTTAAAC 
704 ARG8_Del_For GGATTCGATATGGTTGCCAGCTCGCTATGTGACTCACTTACGGATCCCCGGGTTAATTAA 
705 ARG1_Chk_Rev CGGATCGTACAACTTTTCAG 
706 ARG1_Chk_For GCCGTATGGAAGAGTCATTT 
707 ARG8_Chk_Rev TCAAGGTATGAAAGACGCAC 
708 ARG8_Chk_For GCTCATAGCAATCGCGAAAT 
709 HIS2_NEW_ChF AAACGTCTGGAGGAATGACT 
710 HIS2_NEW_ChR TAAAAGCGCGGAAACATGAG 
Table C.1 List of primers in numerical order (continuation)
711 F_pRS315_UBP6 AGCTCTAGACGGTGGTGTCTTAATGGTT 
712 R_pRS315_UBP6 TTAAGGATCCATGGGGGTGCCAAAGGTAAA 
713 HIS2-M GGAATGGAGATCGAAAGTTG 
714 G418-M ATCAGGTGCGACAATCTATC 
715 SLA1_Del_F CCTATAAAATCTTAAAATACATTAATCTAGAATCCAAACGGCGGATCCCCGGG 
716 SLA1_Del_R GACAGAGTGTGTTATATACAAAAGAGCTAGAGTATGACGAATTCGAGCTCGTT 
717 SPE1_Del_F TTTGTGTACAATGGCGTACAGTGGTGGACAGGAAAAATGCGAATTCGAGCTCGTTTAAAC 
718 SPE1_Del_R CTGAGACAGTAGAGAATTGATACATGGATAACTGAATCTCCGGATCCCCGGGTTAATTAA 
719 SPE1_Chk_F AATTCGTCCCCGAACGCAAC  
720 SPE1_Chk_R ATGGCGTACAGTGGTGGACA 
721 pRS315_UMP1_F ATGTTCTAGATATCACTGGCGCTGTATGGCCG 
722 pRS315_UMP1_R CACCGGAGGGGCCCGGAAGGTAAAAGCTCAAGGA 
723 pRS316-GAL_UMP1_F CACCAAGCTTATGAATATCGTCCCACAAGA 
724 pRS316-GAL_UMP1_R GAAATCTAGAGCAATTTTTAAATGCCTAATTG 
725 SLA1-M-Rev CCAGAGAACTCCTAGATGAA 
726 SLA1-M-For TTCATCTAGGAGTTCTCTGG 
727 ChF_Arg4 ACTCATTGGCAGAATCCCGA 
728 ChR_Arg4 TTGACTGCGGACCTGAACTT 
729 ChkPL5’ TCACCAAGCACTGAGCGTCC 
730 ChkPL3’ CTAACTACGGACTGGGGCAA 
Table C.1 List of primers in numerical order (continuation)
731 ChkPR5’ CATAGCTCTCGCAGAGAAGA 
732 ChkPR3’ CAGTCGATGTCTCTAACACC 
733 SCE.2 CTGTTCGATGTTCAGTTCGA 

































747 Chk-Rg3-LEU2-5’ AGCACTCCACAGTTGCAAGA 
748 Chk-Rg1-LEU2-5’ TTACCCAATGGACATCTAGT 
756 Chk-Rg1-LEU2-Rev TAGCATTGCTCAGAGTTAGA 
Table C.1 List of primers in numerical order (continuation)
757 Chk-Rg3-LEU2-Rev TCCGGATTCCGTCCTCTTAT 
758 M-Leu2-Rev TCACTATCCCAAGCGACACC 
759 Rg1-FrL-5’ TAAGTGGTGGGACGTATGCC 
760 Rg1-FrL-3’ TGTCCATTGGGTAACCCAGC 
761 Rg1-HiL-5’ TAGGGCCAAGAACGTGGTGG 
762 Rg1-HiL-3’ TGCAACAAGGGCTTTGTCAC 
763 M-LEU2-For TGGTGTCGCTTGGGATAGTG 
764 Rg3-Seq-5’ AAACGAATGGAGGACGAGC 









770 Chk-Rg2-LEU2-3’ CGTTTGCGGTGGCGGTGAAG 
771 Chk-Rg3.1-LEU2-5’ GAAAGTGTGTTTCCGTTGCC 
772 Chk-Rg3.2-LEU2-5’ GTGCTGCCACTTCAGACTCC 
773 Chk-Rg2.1-LEU2-3’ ACAGCGACGGAACAGCGGTG 

















788 Chk-2.1a-3’ AATCCCGCATCGTTTATCCC 
789 Chk-2.1b-5’ TGGCTATATTCGGAGGAGGC 
790 Chk-2.1b-3’ TGGTCCCGAGCACAGCCAAG 
791 Chk-2.1c-5’ CAAGGCAGTGCGAAGCGGTG 
792 Chk-2.1c-3’ GTGGAGGTACACGGGTATGC 
793 Chk-2.1d-5’ CCATAGCTTGTCGATTGCTC 
794 Chk-2.1d-3’ AGGACGATGCTAAAGTTGCC 
795 Chk-2.1e-5’ CCTAATGCGATACGTCTTCC 
796 Chk-Npl4-Del-P.I CGACTCCCAGTTATTGTTCC 
797 Chk-Npl4-Del-P.II TTGTGCGTACCTCTTTCCTG 
798 Chk-Ubs1-Del-P.I AGTTCCGAGAACATTCTGCC 

































































Table C.1 List of primers in numerical order (continuation)
816 Chk-IRA1-5’ GGCTGGGAAACCATGCTTGG 
817 Chk-IRA1-3’ CCCTCTAAGCGAGCCGACAC 
818 Mid-IRA1-5’ ATTCGCCTGTCCTAGTGTTG 
819 Chk-MAK5-5’ CCGCTGTATTAGTGGTATCG 
820 Chk-MAK5-3’ GGTATTGGTGCCATGCTGCG  
821 Del-IRA1-5’ AACCTTGCAATCATTATACTTTACACAAATCTCTACGTTTAAGAAGCAAGCACACAATGG 
822 Del-IRA1-3’ TAAAGTCAAGTGATCATCTTTTGCCCTGCAAATAGAGCTTCTGTTTAGCTTGCCTCGTCC 
823 Del-MAK5-5’ TTTCACCTCACAAACCCGCCTCAAGGTTAGTTAGTCCGTAAAGAAGCAAGCACACAATGG 
824 Del-MAK5-3’ ACATAGTGGGTTTAGAGGACCGTGTATATTACGTAGAAAACTGTTTAGCTTGCCTCGTCC 
825 Del-IRA1-S2-5’ CTTGAAAATTAGGGCCAAGAACGTGGTGGTATCATCGGGTAAGAAGCAAGCACACAATGG 
826 Del-IRA1-S2-3’ ATTTGAGCACTCTGAAAAGAACCTGGGCATTTCAAATCATCTGTTTAGCTTGCCTCGTCC 
827 Del-IRA1-S3-5’ ATGATTTGAAATGCCCAGGTTCTTTTCAGAGTGCTCAAATAAGAAGCAAGCACACAATGG 
828 Chk-IRA1-S2-3’ TTGATACCAGAGCAAGCATC 
829 Hyg-For GCCTCGCTCCAGTCAATGAC 
830 Hyg-Rev GTCATTGACTGGAGCGAGGC 
831 Del-RTC2-5’ ACGTAATAGCCTCAAGCGAGCATCCCTAAATTTCTGCCATAAGAAGCAAGCACACAATGG 
832 Del-RTC2-3’ TCTGGGCTATAGCCGATGCGCATATGAGTAAGTTTGAGTTCTGTTTAGCTTGCCTCGTCC 
833 Del-ARA1-5’ GAGGGGGATATCAAGCATCTGGACTTATTTGCACTATCTCAAGAAGCAAGCACACAATGG 
Table C.1 List of primers in numerical order (continuation)
834 Del-ARA1-3’ GTCCAAGTTTGGTCCGTTACCAGTAAACTCTGGAAGGATGCTGTTTAGCTTGCCTCGTCC 
835 Del-TBS1-5’ AAGTATCTGAAATACATACGCGCGCGTATGCATATGTATTAAGAAGCAAGCACACAATGG 
836 Del-TBS1-3’ GATTACAAGCCCAGCAGGAGTTGTGTGAATGAATATGGATCTGTTTAGCTTGCCTCGTCC 
837 Chk-RTC2-5’ TTCCTCTCACCCGCAAAGC 
838 Chk-RTC2-3’ CGTGTCAGCAAAGGGCATCG 
839 Chk-ARA1-5’ CTACCCTTACCTCCGCCTGG 
840 Chk-ARA1-3’ TTAGCTTCGCTGCTTGATGC 
841 Chk-TBS1-5’ TGGGACGAAGTGGACAGATC 
842 Chk-TBS1-3’ AGCCACTGCCCAAAGTCTAC 
859 Chk-IRA1-S3-5’ ACATCAGCAGGAGAACACGC 
860 Chk-SUP45-5’ AGATTAGCAGGCGAACTGGC 
861 Chk-SUP45-3’ CAATCTGTCGCTACCGCATG 
862 Chk-ADH5-3’ CTTACGCACGCAGTTGCTAG 
873 Del-SUP45-5’ TTTTCTACGTAATATACACGGTCCTCTAAACCCACTATGTAAGAAGCAAGCACACAATGG 
874 Del-SUP45-3’ TTAATTCATTTCGGCTTGTCTCCTTATTAAGACTACAGAACTGTTTAGCTTGCCTCGTCC 
875 Del-ADH5-3’ ATGTCCACCGGTTCTCGCAAAGTACAGAATCACTCGCTATCTGTTTAGCTTGCCTCGTCC 
911 Chk-Rg3.2X-5’ CGCTGCTCGTCCTGGGTGA 
912 Chk-Rg3.2X-3’ GCTACGCTGGTTGAGTGGAAG 
913 Chk-Rg3.2XI-3’ GAGAGTGGAATAACGGGTCG 
914 Chk-Rg3.2XII-5’ GTATGCCCAAGACCAGTCGG 
Table C.1 List of primers in numerical order (continuation)
915 Rg3.2X-Del-5’ ACAATCAACGACAGTTCGCGCTTCCCTCACTAAATATGGCCAACAAGTAATTGGTTGTTT 
916 Rg3.2X-Del-3’ TTTATACATTCGACAATGTACTTCGCCAGGGGACCGGCCGCTACGTCGTTAAGGCCGTTT 
917 Rg3.2XI-3’ AAGATCCTTACATTACACGGCGTGCGACAGACTCGAACCACTACGTCGTTAAGGCCGTTT 
918 Rg3.2XII-5’ TGGTTCGAGTCTGTCGCACGCCGTGTAATGTAAGGATCTTCAACAAGTAATTGGTTGTTT 
919 Chk-Rg3.2XI-Rev CGACCAGAACCCGTGGTATG 
920 Chk-Rg3.2XII-For CAACTGGCTAAGGTGAACGG 
 
Table C.1 List of primers in numerical order (continuation)
APPENDIX D 
CGH DATA OF AQT DERIVATIVES 
 
The microarray experiment was performed by our collaborator, Dr. Piotr 
Mieczkowski (University of North Carolina). For the data of the CGH analysis of AQT 
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